

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Psoriatic arthritis | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1665/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1665" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Psoriatic arthritis" />
    
            <meta name="og:title" content="F1000Research Article: Psoriatic arthritis.">
            <meta name="og:description" content="Read the latest article version by Vanessa Ocampo D, Dafna Gladman, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="20979">
            <meta name="article-id" content="19144">
            <meta name="dc.title" content="Psoriatic arthritis">
            <meta name="dc.description" content="Psoriasis is a multisystemic, inflammatory skin condition that can affect many areas of the body, but most commonly the extensor surfaces of the elbows and knees, and sometimes the intergluteal and umbilical area. It has a prevalence of 2&ndash;4% in western adults, and 20&amp;shy;&ndash;30% of psoriasis patients will develop psoriatic arthritis (PsA). PsA is an inflammatory musculoskeletal disease associated with cutaneous psoriasis. It affects men and women almost equally with a peak age at onset of 40 and 50 years. It is a diverse disease that affects multiple organ systems includes peripheral and axial joints, entheses, skin, and nails. PsA is associated with comorbidities such as osteoporosis, uveitis, subclinical bowel inflammation, and cardiovascular disease. Given this heterogeneity, its diagnosis has been difficult. Here we present an updated review of its classification criteria CASPAR (classification criteria for PsA), use of screening tools to aid in early diagnosis, recent findings on pathogenesis, and new therapeutic approaches including new biologic medications.">
            <meta name="dc.subject" content="psoriatic arthritis, pathogenesis, treatment, biomarkers">
            <meta name="dc.creator" content="Ocampo D, Vanessa">
            <meta name="dc.creator" content="Gladman, Dafna">
            <meta name="dc.date" content="2019/09/20">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.19144.1">
            <meta name="dc.source" content="F1000Research 2019 8:1665">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="psoriatic arthritis">
            <meta name="prism.keyword" content="pathogenesis">
            <meta name="prism.keyword" content="treatment">
            <meta name="prism.keyword" content="biomarkers">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/09/20">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1665">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.19144.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1665">
            <meta name="citation_title" content="Psoriatic arthritis">
            <meta name="citation_abstract" content="Psoriasis is a multisystemic, inflammatory skin condition that can affect many areas of the body, but most commonly the extensor surfaces of the elbows and knees, and sometimes the intergluteal and umbilical area. It has a prevalence of 2&ndash;4% in western adults, and 20&amp;shy;&ndash;30% of psoriasis patients will develop psoriatic arthritis (PsA). PsA is an inflammatory musculoskeletal disease associated with cutaneous psoriasis. It affects men and women almost equally with a peak age at onset of 40 and 50 years. It is a diverse disease that affects multiple organ systems includes peripheral and axial joints, entheses, skin, and nails. PsA is associated with comorbidities such as osteoporosis, uveitis, subclinical bowel inflammation, and cardiovascular disease. Given this heterogeneity, its diagnosis has been difficult. Here we present an updated review of its classification criteria CASPAR (classification criteria for PsA), use of screening tools to aid in early diagnosis, recent findings on pathogenesis, and new therapeutic approaches including new biologic medications.">
            <meta name="citation_description" content="Psoriasis is a multisystemic, inflammatory skin condition that can affect many areas of the body, but most commonly the extensor surfaces of the elbows and knees, and sometimes the intergluteal and umbilical area. It has a prevalence of 2&ndash;4% in western adults, and 20&amp;shy;&ndash;30% of psoriasis patients will develop psoriatic arthritis (PsA). PsA is an inflammatory musculoskeletal disease associated with cutaneous psoriasis. It affects men and women almost equally with a peak age at onset of 40 and 50 years. It is a diverse disease that affects multiple organ systems includes peripheral and axial joints, entheses, skin, and nails. PsA is associated with comorbidities such as osteoporosis, uveitis, subclinical bowel inflammation, and cardiovascular disease. Given this heterogeneity, its diagnosis has been difficult. Here we present an updated review of its classification criteria CASPAR (classification criteria for PsA), use of screening tools to aid in early diagnosis, recent findings on pathogenesis, and new therapeutic approaches including new biologic medications.">
            <meta name="citation_keywords" content="psoriatic arthritis, pathogenesis, treatment, biomarkers">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Vanessa Ocampo D">
            <meta name="citation_author_institution" content="University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada">
            <meta name="citation_author" content="Dafna Gladman">
            <meta name="citation_author_institution" content="University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada">
            <meta name="citation_author_institution" content="Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada">
            <meta name="citation_publication_date" content="2019/09/20">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1665">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.19144.1">
            <meta name="citation_firstpage" content="1665">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1665/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1665.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=20979 /> <input type=hidden id=articleId name=articleId value=19144 /> <input type=hidden id=xmlUrl value="/articles/8-1665/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1665-v1.xml"> <input type=hidden id=article_uuid value=15c91bca-429c-461e-8661-7646383e3cc6 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Psoriatic arthritis"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.19144.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.19144.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1665"
  },
  "headline": "Psoriatic arthritis",
  "datePublished": "2019-09-20T13:54:17",
  "dateModified": "2019-09-20T13:54:17",
  "author": [
    {
      "@type": "Person",
      "name": "Vanessa Ocampo D"
    },    {
      "@type": "Person",
      "name": "Dafna Gladman"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Psoriasis is a multisystemic, inflammatory skin condition that can affect many areas of the body, but most commonly the extensor surfaces of the elbows and knees, and sometimes the intergluteal and umbilical area. It has a prevalence of 2&ndash;4% in western adults, and 20&amp;shy;&ndash;30% of psoriasis patients will develop psoriatic arthritis (PsA). PsA is an inflammatory musculoskeletal disease associated with cutaneous psoriasis. It affects men and women almost equally with a peak age at onset of 40 and 50 years. It is a diverse disease that affects multiple organ systems includes peripheral and axial joints, entheses, skin, and nails. PsA is associated with comorbidities such as osteoporosis, uveitis, subclinical bowel inflammation, and cardiovascular disease. Given this heterogeneity, its diagnosis has been difficult. Here we present an updated review of its classification criteria CASPAR (classification criteria for PsA), use of screening tools to aid in early diagnosis, recent findings on pathogenesis, and new therapeutic approaches including new biologic medications."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1665",
            "name": "Psoriatic arthritis"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Psoriatic arthritis </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=20979 data-id=19144 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19144.1" data-recommended="" data-doi="10.12688/f1000research.19144.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1665/v1/pdf?article_uuid=15c91bca-429c-461e-8661-7646383e3cc6" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-19144-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-19144-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-19144-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Ocampo D V and Gladman D. Psoriatic arthritis [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1665 (<a class=new-orange href="https://doi.org/10.12688/f1000research.19144.1" target=_blank>https://doi.org/10.12688/f1000research.19144.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-19144-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=19144 id=track-article-signin-19144 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19144?target=/articles/8-1665">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20979 /> <input name=articleId type=hidden value=19144 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Psoriatic arthritis</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Vanessa Ocampo D<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:dafna.gladman@utoronto.ca" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Dafna Gladman</span></a><a href="https://orcid.org/0000-0002-9074-0592" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-9074-0592</div><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Vanessa Ocampo D<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:dafna.gladman@utoronto.ca" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Dafna Gladman</span></a><a href="http://orcid.org/0000-0002-9074-0592" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-9074-0592</div><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 20 Sep 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.19144.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada<br/> <sup>2</sup> Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada<br/> <p> <div class=margin-bottom> Vanessa Ocampo D <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Dafna Gladman <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=56925-53737></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=56926-53738></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Psoriasis is a multisystemic, inflammatory skin condition that can affect many areas of the body, but most commonly the extensor surfaces of the elbows and knees, and sometimes the intergluteal and umbilical area. It has a prevalence of 2–4% in western adults, and 20&shy;–30% of psoriasis patients will develop psoriatic arthritis (PsA). PsA is an inflammatory musculoskeletal disease associated with cutaneous psoriasis. It affects men and women almost equally with a peak age at onset of 40 and 50 years. It is a diverse disease that affects multiple organ systems includes peripheral and axial joints, entheses, skin, and nails. PsA is associated with comorbidities such as osteoporosis, uveitis, subclinical bowel inflammation, and cardiovascular disease. Given this heterogeneity, its diagnosis has been difficult. Here we present an updated review of its classification criteria CASPAR (classification criteria for PsA), use of screening tools to aid in early diagnosis, recent findings on pathogenesis, and new therapeutic approaches including new biologic medications. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> psoriatic arthritis, pathogenesis, treatment, biomarkers </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Dafna Gladman (<a href="mailto:dafna.gladman@utoronto.ca">dafna.gladman@utoronto.ca</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Dafna Gladman </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> DG has received consulting fees and/or grant support from Abbvie, Amgen, Bristol-Myers Squibb (BMS), Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer, and Union Chimique Belge (UCB). VOD has no competing interests to disclose. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Ocampo D V and Gladman D. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Ocampo D V and Gladman D. Psoriatic arthritis [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1665 (<a href="https://doi.org/10.12688/f1000research.19144.1" target=_blank>https://doi.org/10.12688/f1000research.19144.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 20 Sep 2019, <b>8</b>(F1000 Faculty Rev):1665 (<a href="https://doi.org/10.12688/f1000research.19144.1" target=_blank>https://doi.org/10.12688/f1000research.19144.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 20 Sep 2019, <b>8</b>(F1000 Faculty Rev):1665 (<a href="https://doi.org/10.12688/f1000research.19144.1" target=_blank>https://doi.org/10.12688/f1000research.19144.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d32882e152>Introduction</h2><p class="" id=d32882e155>Psoriasis is a multisystemic, chronic inflammatory skin condition manifesting with scaly erythematous plaques most commonly affecting extensor surfaces of the elbows and knees, and sometimes the intergluteal and umbilical area<sup><a href="#ref-1">1</a></sup>, and other parts of the body<sup><a href="#ref-1">1</a></sup>. It has a prevalence of 2–4% in Western adults<sup><a href="#ref-2">2</a></sup>, and 20–30% of psoriasis patients will develop psoriatic arthritis (PsA)<sup><a href="#ref-3">3</a></sup>. In a prospective study of 464 patients with psoriasis who were confirmed not to have inflammatory arthritis at presentation to the clinic, 51 developed PsA during an 8-year follow-up, for an annual incidence of 2.7%<sup><a href="#ref-4">4</a></sup>.</p><p class="" id=d32882e178>PsA is an inflammatory musculoskeletal disease associated with cutaneous psoriasis. It affects men and women almost equally between the ages of 40 and 50 years<sup><a href="#ref-5">5</a></sup>. The diversity of affected organ systems includes peripheral and axial joints, entheses, skin, and nails. PsA is associated with comorbidities such as osteoporosis, uveitis, subclinical bowel inflammation, and cardiovascular disease<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>. Given this heterogeneity, its diagnosis has been difficult. However, classification criteria such as CASPAR (classification criteria for PsA)<sup><a href="#ref-8">8</a></sup> and several screening tools have facilitated the recognition of this disease among family physicians, dermatologists, and rheumatologists.</p><p class="" id=d32882e196>Up until 20 years ago, there were not many very effective treatments for PsA. Thankfully, over the last decade, there has been a revolution of new therapies with biologics, leading to better control of the disease and its consequent complications and comorbidities. We now know that early diagnosis is important if we are to prevent damage in patients with PsA. This article reviews PsA early diagnosis, recent findings in pathogenesis, and new therapeutic approaches.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d32882e202>Early diagnosis in psoriatic arthritis</h2><p class="" id=d32882e205>Delayed PsA diagnosis has been shown to be associated with worse physical function<sup><a href="#ref-9">9</a></sup>. Haroon <i>et al</i>. demonstrated that even a 6-month delay from symptom onset to the first visit to the rheumatologist (delay in consultation) resulted in worse outcome for patients with PsA, with more peripheral joint erosions, sacroiliitis, and worse health assessment questionnaire (HAQ) scores<sup><a href="#ref-10">10</a></sup>. This population of patients has increased frequency of cardiovascular disease, diabetes, metabolic syndrome, and depression, which in some cases is triggered by the persistent inflammatory state in untreated PsA<sup><a href="#ref-11">11</a></sup>. But how can we diagnose PsA earlier?</p><div class=section><a name=d32882e223 class=n-a></a><h3 class=section-title>Clinical features</h3><p class="" id=d32882e228>Clinical features of the disease may help to identify patients with psoriasis at risk of developing arthritis. Psoriasis severity increases the risk for PsA, as shown in a large cohort study<sup><a href="#ref-12">12</a></sup>. Having more than three body sites affected by psoriasis (compared to one site) was associated with a 2.24-fold increased risk of PsA<sup><a href="#ref-13">13</a></sup>. The location of psoriasis can increase the risk of PsA; one study found a 3.98-fold increase in PsA with scalp lesions and another identified a 2.35-fold increase with intergluteal and perianal lesions<sup><a href="#ref-13">13</a></sup>. Conversely, as scalp and intergluteal lesions are so often observed in psoriasis, they may not reliably indicate which patients should be referred to a rheumatologist. Nail lesions occur in over 80% of patients with PsA compared to about 40% of patients with psoriasis without arthritis<sup><a href="#ref-14">14</a>,<a href="#ref-15">15</a></sup>. A prospective study of 464 patients with psoriasis who were confirmed not to have inflammatory arthritis at presentation to the clinic found that 51 developed PsA during an 8-year follow-up. Baseline variables found as risk factors for the development of PsA were severe psoriasis, low level of education, and the use of retinoids. In a time-dependent analysis, nail pitting and uveitis remained significant in a multivariate model<sup><a href="#ref-4">4</a></sup>.</p></div><div class=section><a name=d32882e255 class=n-a></a><h3 class=section-title>Classification criteria</h3><p class="" id=d32882e260>Even though the CASPAR criteria were established in patients with long-standing disease, studies have shown that they work well in patients with early disease<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>. Only rheumatologists can accurately make a diagnosis using these criteria, and that is why screening tools were created.</p></div><div class=section><a name=d32882e271 class=n-a></a><h3 class=section-title>Screening tools</h3><p class="" id=d32882e276>The development of screening tools has aided the early detection of PsA. The most frequently used are the Toronto PsA Screen (ToPAS), the Psoriasis Arthritis Screening and Evaluation Questionnaire (PASE), and the Psoriasis Epidemiology Screening Tool (PEST). Despite these screening tools demonstrating good sensitivity and specificity during their development, they did not function very well in the real-world setting<sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a></sup>. A study from 2015 suggested that adding axial involvement to the ToPAS (ToPAS 2) questionnaire increases the sensitivity of the test as a screening tool, as axial disease is more likely to be part of the PsA spectrum<sup><a href="#ref-20">20</a></sup>. Other tools are the early psoriatic arthritis screening questionnaire (EARP), which was validated in 2012<sup><a href="#ref-21">21</a></sup>; the Screening Tool for Rheumatologic Investigation in Psoriatic Arthritis (STRIPP), which was developed by an Italian group of investigators<sup><a href="#ref-22">22</a></sup> and showed good sensitivity and specificity but needs additional validation; and the Simple Psoriatic Arthritis Screening questionnaire (SiPAS), which was validated by the Italian group led by Salaffi, who demonstrated that having &gt;3 out of 5 questions answered “yes” showed a sensitivity of 79% and specificity of 87% (+likelihood ratio [LR] 6.14)<sup><a href="#ref-23">23</a></sup>. See <a href="#T1">Table 1</a> for a summary of the screening tools.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Screening questionnaires for psoriatic arthritis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d32882e317 class=n-a></a><thead><a name=d32882e319 class=n-a></a><tr><a name=d32882e321 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d32882e323 class=n-a></a>SCREENING TOOLS</th><th align=left colspan=1 rowspan=1 valign=top><a name=d32882e326 class=n-a></a>DESCRIPTION</th><th align=left colspan=1 rowspan=1 valign=top><a name=d32882e329 class=n-a></a>SENSITIVITY/SPECIFICITY</th></tr></thead><tbody><a name=d32882e334 class=n-a></a><tr><a name=d32882e336 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e338 class=n-a></a>ToPAS<a href="#FN1">*</a><sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a></sup> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e350 class=n-a></a>Self-administered<br class=br>11 questions + pictures and diagrams<br class=br>Max score: N/A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e357 class=n-a></a>Sensitivity: 70–86.8%<br class=br>Specificity: 93.1%</td></tr><tr><a name=d32882e363 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e365 class=n-a></a>PASE<a href="#FN1">*</a> <sup><a href="#ref-18">18</a></sup> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e375 class=n-a></a>Self-administered<br class=br>15 questions<br class=br>Max score: 75</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e382 class=n-a></a>Sensitivity: 59–82%<br class=br>Specificity: 66–73%</td></tr><tr><a name=d32882e388 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e390 class=n-a></a>ToPAs 2<sup><a href="#ref-21">21</a>–<a href="#ref-82">82</a></sup> </td><td colspan=1 rowspan=1><a name=d32882e400 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e402 class=n-a></a>Sensitivity: 44%<br class=br>Specificity: 97%</td></tr><tr><a name=d32882e408 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e410 class=n-a></a>EARP<sup><a href="#ref-21">21</a></sup> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e417 class=n-a></a>Self-administered<br class=br>9 questions<br class=br>Max score: 10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e424 class=n-a></a>Sensitivity: 85%<br class=br>Specificity: 78–85%</td></tr><tr><a name=d32882e430 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e432 class=n-a></a>STRIPP<sup><a href="#ref-22">22</a></sup> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e439 class=n-a></a>Self-administered</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e442 class=n-a></a>Sensitivity: 91.5%<br class=br>Specificity: 93.3%</td></tr><tr><a name=d32882e449 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e451 class=n-a></a>SiPAS<sup><a href="#ref-23">23</a></sup> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e458 class=n-a></a>Self-administered<br class=br>5 questions<br class=br>Max score: 5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e465 class=n-a></a>Sensitivity: 79%<br class=br>Specificity: 87%</td></tr><tr><a name=d32882e471 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e473 class=n-a></a>PEST<a href="#FN1">*</a><sup><a href="#ref-83">83</a></sup> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e482 class=n-a></a>Self-administered<br class=br>5 questions + joint diagram<br class=br>Max score: N/A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e489 class=n-a></a>Sensitivity: 68–97%<br class=br>Specificity: 71–79%</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d32882e499 class=n-a></a><p id=d32882e501> *Table adapted from article by Machado <i>et al</i>.<sup><a href="#ref-84">84</a></sup></p></div></div></div></div><div class=section><a name=d32882e515 class=n-a></a><h3 class=section-title>Sonography</h3><p class="" id=d32882e520>Sonography has a role in identifying early PsA patients<sup><a href="#ref-5">5</a></sup>, mostly those who do not have the “classic” initial clinical picture. Gisondi <i>et al</i>. used the Glasgow Ultrasound Enthesis Scoring System (GUESS) to compare the enthesis of patients with psoriasis versus controls. They found that the mean GUESS score was higher and the entheses were thicker in psoriasis patients compared to controls. In a 2-year follow up, they found that 3 out of the 30 patients developed PsA<sup><a href="#ref-24">24</a></sup>.</p><p class="" id=d32882e534>In 2019, the GRAPPA ultrasound working group assessed the performance of various sonographic elemental entheseal lesions in distinguishing between PsA and controls, with the aim of informing the development of a novel sonographic enthesitis score for PsA<sup><a href="#ref-25">25</a></sup>. They found that the best model, which gave an area under the curve of 0.93, included lesions such as enthesophytes, Doppler signal, erosions, thickening, and hypoechogenicity and six entheseal sites (patellar ligament insertions into the distal patella and tibial tuberosity, Achilles tendon and plantar fascia insertions into the calcaneus, common extensor tendon insertion into lateral epicondyle, and supraspinatus insertion into the superior facet of the humerus<sup><a href="#ref-24">24</a></sup>).</p></div><div class=section><a name=d32882e546 class=n-a></a><h3 class=section-title>Biomarkers</h3><p class="" id=d32882e551>A biological marker is any component identified via genomic transcription, proteomic, cellular, or imaging approaches that is associated with the pathophysiology, clinical course, or outcome of a specific disease<sup><a href="#ref-26">26</a></sup>. For clinicians (especially family doctors, dermatologists, and rheumatologists), having a biomarker would facilitate the identification of individuals likely to develop PsA.</p><p class="" id=d32882e558><b><i>Genomic biomarkers.</i></b> The HLA alleles that distinguish patients with PsA from those with psoriasis without arthritis have been identified and replicated. The heterogenicity between PsA and psoriasis without PsA may be driven by HLA-B amino acid position 45<sup><a href="#ref-27">27</a></sup>. A study of 712 patients with PsA and 335 patients with psoriasis confirmed not to have arthritis by a rheumatologist demonstrated that the HLA alleles B*08, B*27, and B*38 are risk factors for the development of PsA, whereas HLA-C*06 is “protective”<sup><a href="#ref-28">28</a></sup>. HLA-B*27 was associated with early development of PsA among patients with psoriasis, whereas the presence of HLA-C*06 was associated with a delayed onset of PsA<sup><a href="#ref-29">29</a></sup>. HLA-B*27:05:02 is associated with increased risk of enthesitis, dactylitis, and symmetric sacroiliitis, whereas HLA-B*08:01:01 and HLA-C*07:01:01 haplotypes are associated with joint fusion and deformities, asymmetrical sacroiliitis, and dactylitis<sup><a href="#ref-30">30</a></sup>. Recent genome-wide association studies (GWAS) have identified SNPs near <i>HLA-C</i>, <i>TNFRSF9</i>, and <i>LCE3A</i> as more strongly associated with psoriasis than PsA, whereas SNPs near <i>IL-23R</i> and <i>TNFAIP3</i> were more strongly associated with PsA than PsC<sup><a href="#ref-31">31</a></sup>. Other genes identified as potential biomarkers for PsA are <i>NOTCH2NL</i>, <i>HAT1</i>, <i>CXCL10</i>, and <i>SETD2</i><sup><a href="#ref-32">32</a></sup>.</p><p class="" id=d32882e616><b><i>Soluble biomarkers.</i></b> The markers CRP (hs-CRP), OPG, MMP-3, and the CPII:C2C ratio were found to distinguish patients with PsA from those with psoriasis without arthritis<sup><a href="#ref-33">33</a></sup>. In recent years, C-X-C motif chemokine 10 (CXCL10) was found to be a biomarker for the development of PsA in patients with psoriasis<sup><a href="#ref-34">34</a></sup>. Those who went on to develop PsA had higher serum levels of CXCL10 than those who did not. Additionally, serum CXCL10 dropped after PsA development. Upon examination of paired serum and synovial fluid samples from PsA patients, higher levels were seen in the synovial fluid in comparison to the blood; this indicates that CXCL10 may be a biomarker for the development of PsA in patients suffering from psoriasis and could be pathogenetically involved in its development<sup><a href="#ref-35">35</a></sup>. One group described that between cellular biomarkers, osteoclast precursor (OCP) was found in one-third of patients with psoriasis alone and in the majority of patients with PsA<sup><a href="#ref-36">36</a></sup>. An increase in OCP correlated with erosive disease. They also developed an antibody against a dendritic cell-specific transmembrane protein (DC-STAMP) which was associated with OCPs and could be an additional biomarker for identifying PsA early. These biomarkers are now being examined in psoriasis patients who go on to develop PsA<sup><a href="#ref-37">37</a></sup>.</p><p class="" id=d32882e642>With the advantages of all of these new biomarkers, we hope to have an earlier and accurate detection of these patients and treat them accordingly, but, since this is a multifactorial disease, it is likely that there will not be one biomarker but rather a combination of biomarkers.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d32882e649>Pathogenesis of psoriatic arthritis</h2><p class="" id=d32882e652>PsA pathogenesis involves multiple different factors, including genetic, immunologic, and environmental factors.</p><div class=section><a name=d32882e655 class=n-a></a><h3 class=section-title>Environmental factors</h3><p class="" id=d32882e660>There is an association between upper respiratory airway streptococcal infection and guttate psoriasis. Vasey <i>et al</i>. found elevated levels of the Streptococcus exotoxin antibody anti-deoxyribonuclease B in PsA, but it was absent in patients with psoriasis alone<sup><a href="#ref-38">38</a></sup>.</p><p class="" id=d32882e670>Pattison <i>et al</i>.<sup><a href="#ref-39">39</a></sup> compared the prevalence of environmental exposures among 98 British PsA and 163 psoriasis patients over a window of exposure that ranged from 5–10 years prior to the onset of arthritis. They identified physical trauma, rubella vaccination, oral ulcers, and moving to a new house as being associated with PsA. In 2011, Eder <i>et al</i>.<sup><a href="#ref-40">40</a></sup> found in a case-control study that infections that required antibiotic treatment, injuries, and occupations that involved lifting heavy weights were associated with PsA, while there was an inverse association with smoking.</p><p class="" id=d32882e687>Among other factors, there is some evidence regarding obesity<sup><a href="#ref-41">41</a></sup> and mechanical stress or trauma (Deep Koebner phenomenon). PsA patients have evidence of enthesophyte formation at mechanically exposed sites of the joint, while it is absent in healthy controls<sup><a href="#ref-42">42</a></sup>.</p></div><div class=section><a name=d32882e699 class=n-a></a><h3 class=section-title>Genetic factors</h3><p class="" id=d32882e704>Psoriasis and PsA are associated with class I MHC alleles, mainly HLA-C*06, which is a major risk factor for psoriasis but not for PsA<sup><a href="#ref-43">43</a></sup>. HLA-B*27, HLA-B*38, HLA-B*08, and HLA-B*39 have been observed in PsA and associated with some PsA phenotypes<sup><a href="#ref-44">44</a></sup>.</p><p class="" id=d32882e715>The killer-cell immunoglobin-like receptor (KIR) genes were initially proposed in the early 2000s as genes conferring susceptibility to PsA<sup><a href="#ref-45">45</a></sup>. Later, Chandran <i>et al</i>.<sup><a href="#ref-46">46</a></sup> proposed the activating KIR gene, explicitly <i>KIR2DS2</i>, as key in the susceptibility and the pathogenesis of PsA, since KIRs interplay with HLA-B Bw4 and HLA-C to augment the inflammatory response. These genes are coded on chromosome 19 but use the HLA-C molecules as ligands.</p><p class="" id=d32882e732>The endoplasmic reticulum aminopeptidase 1 (ERAP1) product is relevant to peptides binding to the MHC class I molecules, especially HLA-C*0602 and HLA-B*27<sup><a href="#ref-47">47</a></sup>. SNPs related to genes relevant to immune function include loci containing genes involved in NF-kB signaling (<i>REL</i>, <i>TNIP1</i>, <i>NFKBIA</i>, and <i>CARD14</i>), IFN signaling (<i>IL28RA</i> and <i>TYK2</i>), T-cell regulation (<i>RUNX3</i>, <i>IL13</i>, <i>TAGAP</i>, <i>ETS1</i>, and <i>MBD2</i>), and antiviral signaling (<i>IFIH1</i>, <i>DDX58</i>, and <i>RNF114</i>) and genes involved in the IL-23 pathway that specifically implicate a role for T helper type 17 (Th17) cells (<i>TNFAIP3</i>, <i>IL23R</i>, <i>IL12B</i>, <i>TRAF3IP2</i>, <i>IL23A</i>, and <i>STAT3</i>). Most of these have also been identified in PsA, but only two of these loci were independently identified in PsA, namely <i>IL12B</i> and <i>IL23R</i>, with the IL23R SNP being independent to the SNP found in psoriasis alone, and another region on chromosome 5q31 has also been identified as a marker for PsA<sup><a href="#ref-48">48</a></sup>.</p></div><div class=section><a name=d32882e814 class=n-a></a><h3 class=section-title>Immunological factors</h3><p class="" id=d32882e819>T-cells are heavily involved in psoriasis and PsA. Activation of CD8<sup>+</sup> T cells and natural killer (NK) cells in the psoriatic synovium and the disease’s response to therapeutic immunomodulation suggest that the immune system, particularly lymphocytes, has significant influence on PsA pathogenesis<sup><a href="#ref-49">49</a></sup>.</p><p class="" id=d32882e829>When Leijten <i>et al</i>.<sup><a href="#ref-50">50</a></sup> compared PsA patients’ synovial fluid to rheumatoid arthritis synovial fluid, they saw that CD4<sup>+</sup>CD8<sup>+</sup> lymphocytes were increased and that CD4<sup>+</sup> Th17 and type 3 lymphocytes were also increased in the PsA population<sup><a href="#ref-49">49</a></sup>, the same cells that produce IL-17A and IL-22. There are different theories regarding the initial trigger of inflammatory response at multiple sites<sup><a href="#ref-47">47</a>,<a href="#ref-51">51</a></sup>.</p><p class="" id=d32882e860>In the skin, stressed keratinocytes release DNA that binds to the antibacterial peptide LL-37, and this stimulates plasmacytoid dendritic cells to release IFNα. This activates dermal dendritic cells, which will migrate to the draining lymph nodes and trigger T helper type 1 (Th1) and Th17 cells to differentiate. From here, Th1 and Th17 cells will migrate to the dermis and release IL-12, IL-17, IL-22, and TNFα, which promote keratinocyte proliferation.</p><p class="" id=d32882e863>In the gut, there is microbial dysbiosis that may trigger inflammation in the ileocolon and stimulate Th17 cells to release IL-23.</p><p class="" id=d32882e867>When there is trauma or biomechanical stress at the tendon insertion site, IL-23 is released, which activates Th17 cells and cytokines such as IL-22 and TNF, resulting in inflammation, bone erosion, and abnormal bone formation. IL-22 and other factors stimulate mesenchymal cells to differentiate into osteoblasts, forming enthesophytes in peripheral entheses and joints and syndesmophytes in the spine.</p><p class="" id=d32882e870>From nearby entheses or the bloodstream, Th17 cells, OCPs, and dendritic cells reach the joint. While here, OCPs differentiate into osteoclasts thanks to the increased expression of the receptor activator of NF-kB (RANK) ligand (RANKL) by the synoviocytes in the lining, combined with higher levels of TNF, IL-17, and RANKL expressed by infiltrating cells. All of this will lead to synovitis and bone resorption.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d32882e877>Available therapy for psoriatic arthritis</h2><p class="" id=d32882e880>Currently, there are about 17 targeted therapies considered for the management of active PsA; therefore, when assessing a patient, we should consider the major domains being affected (peripheral joints, axial disease, dactylitis, enthesitis, psoriasis, and nail disease) to make an informed decision regarding the pharmacologic therapy to be started. The goals of therapy are to achieve minimal disease activity, optimize functional status and quality of life, prevent structural damage, and avoid or minimize complications (from therapy and untreated disease)<sup><a href="#ref-52">52</a></sup>.</p><p class="" id=d32882e887>Conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) such as sulfasalazine, cyclosporine, and leflunomide have been shown to work for symptom relief with lower-grade evidence for methotrexate. None of these agents slow radiographic progression, help with axial symptoms, or relieve uveitis, enthesis, and dactylitis. When used, they can be considered for the treatment of peripheral arthritis<sup><a href="#ref-53">53</a></sup>.</p><p class="" id=d32882e894>Tumor necrosis factor inhibitors (TNFi) have been available for PsA patients since the 2000’s. These agents have demonstrated their effectiveness treating multiple domains of the disease, including peripheral and axial arthritis, enthesitis, dactylitis, skin psoriasis, and nail disease<sup><a href="#ref-54">54</a></sup>, and reducing radiographic progression. Available agents include etanercept, adalimumab, infliximab, golimumab, and certolizumab pegol<sup><a href="#ref-55">55</a></sup>.</p><p class="" id=d32882e905>In randomized controlled trials (RCTs), infliximab<sup><a href="#ref-56">56</a></sup>, golimumab<sup><a href="#ref-57">57</a>,<a href="#ref-58">58</a></sup>, and certolizumab<sup><a href="#ref-59">59</a></sup> have been shown to be effective for enthesitis and dactylitis, whereas etanercept and adalimumab have been shown to control better enthesitis and dactylitis<sup><a href="#ref-60">60</a>,<a href="#ref-61">61</a></sup>. In 2017, the results of the phase III RAPID-PsA study established the efficacy of certolizumab in PsA patients in whom at least one DMARD previously failed or who previously received treatment with a TNFi<sup><a href="#ref-59">59</a></sup>. In two phase III trials, FUTURE 1 and 2, secukinumab, an IL-17A inhibitor, was tested. The first FUTURE-1 used 10 mg/kg secukinumab intravenously at weeks 0, 2, and 4, followed by subcutaneous secukinumab at a dose of either 150 mg or 75 mg every 4 weeks, or placebo<sup><a href="#ref-63">63</a></sup>. Primary outcome was American College of Rheumatology 20% (ACR20) response at 24 weeks. Significantly higher responses were observed for the two drug-treated groups compared to placebo. Secondary end points, including the ACR50 response and joint structural damage, were significantly better in the secukinumab groups than in the placebo group. FUTURE-2 included three doses: 75, 150, and 300 mg. While there were loading doses in this study, they were subcutaneous, not intravenous<sup><a href="#ref-64">64</a></sup>. The 75 mg dose did not work as well as the higher doses for the joints. The 300 mg was clearly better for the skin. Importantly, in both trials, secukinumab was effective for both TNFi-naïve and TNFi-experienced patients, although the 300 mg dose was more effective for the latter. FUTURE-5<sup><a href="#ref-65">65</a></sup> included 300 and 150 mg doses of secukinumab with a loading dose (LD) and 150 mg without loading dose as well as placebo, all using subcutaneous administration. All treatment groups did better than placebo, and there did not appear to be a difference between 150 mg with or without loading.</p><p class="" id=d32882e948>Another IL-17A inhibitor, ixekizumab, has been approved for PsA treatment. SPIRIT-P1<sup><a href="#ref-66">66</a></sup> included 417 TNF-naïve patients who were randomized to either subcutaneous ixekizumab 80 mg every 2 weeks or ixekizumab 80 mg every 4 weeks both following a loading dose of 160 mg, adalimumab 40 mg every other week, or placebo. Primary outcome was ACR20 at 24 weeks, which was achieved by 31% of the placebo-treated patients, 57% of the ixekizumab 80 mg every 4 weeks, 60% of those treated with ixekizumab every 2 weeks, and 51% of those treated with adalimumab. Ixekizumab improved HAQ scores, was effective for skin and nail disease, dactylitis, and enthesis, and was associated with less progression in radiologic damage<sup><a href="#ref-67">67</a></sup>. It was also effective in patients who had failed TNFi<sup><a href="#ref-62">62</a></sup>. In a new study presented in June 2019 at the EULAR congress, Mease <i>et al</i>. showed that ixekizumab was superior to adalimumab in treating PsA and plaque psoriasis in patients not previously exposed to b-DMARDs and who had an inadequate response to conventional DMARDs. A total of 36% of the ixekizumab group achieved PASI 100 and ACR50 versus 28% of the adalimumab group (<i>P</i> &lt;0.05). Composite treat-to-target outcomes, skin outcomes, enthesitis resolution, and quality of life related to skin were significantly better for the ixekizumab cohort.</p><p class="" id=d32882e969>Ustekinumab, an IL-12/-23 inhibitor, demonstrated efficacy in PsA patients in the phase III trials PSUMMIT 1 and 2. While its efficacy for arthritis is not quite as high as that of the anti-TNF agents, it works very well for psoriasis. It works for dactylitis and enthesitis as well<sup><a href="#ref-69">69</a></sup>.</p><p class="" id=d32882e976>Apremilast came out shortly after. It is a phosphodiesterase-4 inhibitor. In the PALACE 1, 2, and 3 trials, phase III studies, patients who were previously exposed to DMARDs or biologic agents and patients with no exposure (PALACE 4) were studied<sup><a href="#ref-70">70</a>–<a href="#ref-72">72</a></sup> In the PALACE 3 trial, it demonstrated efficacy against placebo in patients who failed conventional DMARDs. The ACR20 response was good, although not as effective as the TNFi agents (ACR20 in 28% [dose of 20 mg twice daily] and 41% [30 mg twice daily] compared to placebo [18%] at week 16 and 56% [20 mg twice daily] and 63% [30 mg twice daily] at week 52). It was also effective for dactylitis and enthesitis. However, the effect on radiographic progression was not tested in these trials. In PALACE 4<b>,</b> DMARD-naïve patients who received apremilast had an increased response to ACR20 (apremilast 20 mg twice daily 28%, apremilast 30 mg twice daily 30.7%, and placebo 15.9%) and ACR50, but not ACR70.</p><p class="" id=d32882e989>Abatacept, a CTLA4-Ig selective T-cell co-stimulation modulator, was proven effective in a phase III trial in PsA<sup><a href="#ref-73">73</a></sup>. In a study of 424 patients with PsA, half of whom received 125 mg of abatacept subcutaneously and the rest placebo, there was a significantly greater improvement with drug compared to placebo (ACR20 39% versus 22%), although the delta (difference between drug treated and placebo response) was lower than with the previously described therapies. The benefit was seen regardless of previous exposure to TNF inhibitors, and there was only modest impact on psoriasis lesions.</p><p class="" id=d32882e996>The Janus kinase (JAK) inhibitor tofacitinib, orally available and already approved for Rheumatoid Arthritis, has been tested in PsA. In OPAL BROADEN, a study of 422 TNFi-naïve patients, 107 received tofacitinib 5 mg twice daily, 104 received tofacitinib 10 mg twice daily, 106 received adalimumab 40 mg subcutaneously every other week, and 105 received placebo<sup><a href="#ref-74">74</a></sup>. The primary outcome was ACR20 response and change in HAQ at 12 weeks. ACR20 response was achieved by 50% of the 5 mg twice daily tofacitinib group and 61% of the 10 mg twice daily tofacitinib group, both statistically significantly different from the placebo group with 33% responders. In the comparator adalimumab-treated group, 52% achieved ACR20 at 12 weeks. HAQ scores were also reduced in all treatment groups compared to placebo. In OPAL BEYOND, 394 patients with inadequate response to TNFi were included. Of those, 131 received tofacitinib 5 mg twice daily, 132 received tofacitinib 10 mg twice daily, and 131 received placebo. ACR20 responses were achieved by 50% of those receiving tofacitinib 5 mg twice daily and 47% of those receiving 10 mg twice daily, compared with 24% of the placebo-treated patients<sup><a href="#ref-75">75</a></sup>. HAQ score reductions were significantly different from placebo with both doses of tofacitinib. There were no new safety signals in either of these two studies.</p><p class="" id=d32882e1007>In early 2019, the results of the SEAM-PsA study were published. Mease <i>et al</i>.<sup><a href="#ref-76">76</a></sup> examined the efficacy of methotrexate monotherapy compared to etanercept alone and the value of combining them both for the treatment of PsA. Patients with PsA were randomized to etanercept 50 mg subcutaneously once a week, methotrexate 20 mg orally once a week, or a combination of both etanercept and methotrexate. The results demonstrated that while methotrexate monotherapy resulted in a 50% ACR20 response<i>,</i> etanercept was superior to methotrexate. Moreover, the combination of etanercept and methotrexate was similar to etanercept alone, except for the skin responses, which were better with the combination. However, it should be noted that the dose of etanercept was 50 mg weekly rather than the psoriasis dose of 50 mg twice weekly.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d32882e1023>Therapies under investigation</h2><p class="" id=d32882e1026>Guselkumab is a human monoclonal antibody directed against the p19 subunit of IL-23; it is already approved for moderate-to-severe psoriasis treatment. In June 2019, the results from phase III trials were announced. DISCOVER 1 (n = 381) and DISCOVER 2 (n = 739) trials compared subcutaneous guselkumab to placebo over 52 and 100 weeks, respectively. The group stated that the medication met the primary end point (ACR20). Result of the trials will be presented soon<sup><a href="#ref-77">77</a></sup>. </p><p class="" id=d32882e1033>Risankizumab is a humanized immunoglobulin monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit and was approved in April 2019 for the treatment of moderate-to-severe plaque psoriasis<sup><a href="#ref-78">78</a></sup>; there is an ongoing phase II trial in PsA<sup><a href="#ref-79">79</a></sup>.</p><p class="" id=d32882e1044>Two JAK1-specific inhibitors, filgotinib<sup><a href="#ref-80">80</a></sup> and upadacitinib, are currently under investigation. <a href="#T2">Table 2</a> documents the currently available therapies for PsA.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d32882e1058>Conclusions</h2><p class="" id=d32882e1061>PsA is a chronic inflammatory disease that comprises a clinical syndrome that could present with skin lesions, peripheral or axial arthritis, dactylitis, or nail lesions<sup><a href="#ref-81">81</a></sup>. Usually, PsA occurs after the development of psoriasis; therefore, screening these patients for the development of PsA is crucial so that they can be identified and treated early in order to decrease delay in consultation and its untoward effects. Despite the availability of multiple screening tools, we still need an algorithm to accurately identify patients early so they can have the benefit of therapy. Fortunately, in the past 10 years, the pathogenesis of PsA has been better understood, leading to several therapies, such as anti-TNFs, anti-IL-12/23, anti-IL-17, and anti-IL-23 agents, plus additional agents under investigation. Therefore, we anticipate that the treatment of PsA will become prompter and more aggressive so that joint damage is minimized. In addition, with the development of better therapies and more control over risk factors, PsA patients can experience fewer comorbidities as well as lowered mortality and improved quality of life and function.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Summary of biologics agents investigated and/or approved in PsA.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d32882e1079 class=n-a></a><thead><a name=d32882e1081 class=n-a></a><tr><a name=d32882e1083 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d32882e1085 class=n-a></a>Agent</th><th align=left colspan=1 rowspan=1 valign=top><a name=d32882e1088 class=n-a></a>Agent description</th><th align=left colspan=1 rowspan=1 valign=top><a name=d32882e1091 class=n-a></a>Study</th><th align=left colspan=1 rowspan=1 valign=top><a name=d32882e1094 class=n-a></a>Dose</th><th align=left colspan=1 rowspan=1 valign=top><a name=d32882e1097 class=n-a></a>Study<br class=br>size</th><th align=left colspan=1 rowspan=1 valign=top><a name=d32882e1103 class=n-a></a>Demographics</th><th align=left colspan=1 rowspan=1 valign=top><a name=d32882e1106 class=n-a></a>ACR20</th><th align=left colspan=1 rowspan=1 valign=top><a name=d32882e1109 class=n-a></a>PASI75</th></tr></thead><tbody><a name=d32882e1114 class=n-a></a><tr><a name=d32882e1116 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1118 class=n-a></a>Certolizumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1121 class=n-a></a>Pegylated humanized<br class=br>anti-TNFα antigen<br class=br>binding fragment<br class=br>(Fab’)<br class=br>Binds soluble and<br class=br>membrane-bound<br class=br>TNFα</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1137 class=n-a></a>RAPID-PsA<sup><a href="#ref-59">59</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1143 class=n-a></a>Loading dose: 400 mg<br class=br>at week 0, 2, and 4, then<br class=br>either 200 mg SC every 2<br class=br>weeks or 400 mg SC every<br class=br>4 weeks<br class=br>VS<br class=br>P</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1159 class=n-a></a>409</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1163 class=n-a></a> <b>Mean age</b> <br class=br>200 mg: 48.2<br class=br>400 mg: 47.1<br class=br>P: 47.3<br class=br> <br class=br> <b>Female (%)</b> <br class=br>200 mg: 53.6<br class=br>400 mg: 54.1<br class=br>P: 58.1<br class=br> <br class=br> <b>Mean duration PsA (years)</b> <br class=br>50 mg: 7.2<br class=br>100 mg: 7.7<br class=br>P: 7.6<br class=br> <br class=br> <b>Prior use 1 DMARD (%)</b> <br class=br>200 mg: 44.2<br class=br>400 mg: 53.3<br class=br>P: 54.4<br class=br> <br class=br> <b>2 DMARDs</b> <br class=br>200 mg: 52.9<br class=br>400 mg: 44.5<br class=br>P: 44.1<br class=br> <br class=br> <b>Prior TNF exposure (%)</b> <br class=br>200 mg: 22.5<br class=br>400 mg: 17.0<br class=br>P: 19.1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1245 class=n-a></a> <b>Week 12</b> <br class=br>200 mg: 58%<br class=br>400 mg: 51.9%<br class=br>P: 24.3%<br class=br> <br class=br> <b>Week 24</b> <br class=br>200 mg: 63.8%<br class=br>400 mg: 56.3%<br class=br>P: 23.5%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1271 class=n-a></a> <b>Week 12</b> <br class=br>200 mg: 46.7%<br class=br>400 mg: 47.4%<br class=br>P: 14%<br class=br> <br class=br> <b>Week 24</b> <br class=br>200 mg: 62.2%<br class=br>400 mg: 60.5%<br class=br>P: 15.1%</td></tr><tr><a name=d32882e1298 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1300 class=n-a></a><b>Adalimumab</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1304 class=n-a></a>Human monoclonal Ab.<br class=br>Binds soluble and<br class=br>membrane-bound TNFα</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1311 class=n-a></a>ADEPT<sup><a href="#ref-60">60</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1317 class=n-a></a>A 40 mg SC every 2 weeks<br class=br>VS P</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1322 class=n-a></a>315</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1326 class=n-a></a> <b>Mean age</b> <br class=br>A: 48.6<br class=br>P: 49.2<br class=br> <br class=br> <b>Male (%)</b> <br class=br>A: 56<br class=br>P: 55<br class=br> <br class=br> <b>Mean duration PsA (years)</b> <br class=br>A: 9.8<br class=br>P: 9.2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1360 class=n-a></a> <b>Week 12</b> <br class=br>A: 58%<br class=br>P: 14%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1370 class=n-a></a> <b>Week 12</b> <br class=br>A: 49%<br class=br> <br class=br> <b>Week 24</b> <br class=br>A: 59%<br class=br>P: 1%</td></tr><tr><a name=d32882e1391 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1393 class=n-a></a><b>Ixekizumab</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1397 class=n-a></a>IL17 inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1400 class=n-a></a>SPIRIT-P1<sup><a href="#ref-66">66</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1406 class=n-a></a>TNF-naïve patients<br class=br>80 mg SC every 2 weeks<br class=br>80 mg SC every 4 weeks<br class=br>following a loading dose of 160 mg,<br class=br>A 40 mg EOW, or P</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1417 class=n-a></a>417</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1421 class=n-a></a> <b>Mean age</b> <br class=br>Every 4 weeks: 49.2<br class=br>Every 2 weeks: 49.8<br class=br>P: 50.6<br class=br>A 40 mg every 2 weeks: 48.6<br class=br> <br class=br> <b>Male (%)</b> <br class=br>Every 4 weeks: 42.1<br class=br>Every 2 weeks: 46.6<br class=br>P: 45.3<br class=br>A 40 every 2 weeks: 50.5<br class=br> <br class=br> <b>Mean duration PsA (years)</b> <br class=br>Every 4 weeks: 13.8<br class=br>Every 2 weeks: 14<br class=br>P: 13.8<br class=br>A 40 mg every 2 weeks: 12.7</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1468 class=n-a></a><b>24 weeks</b><br class=br>80 mg every 2 weeks: 62.1%<br class=br>80 mg every 4 weeks: 57.4%<br class=br>A: 57.9%<br class=br>P: 30.2%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1480 class=n-a></a> <b>24 weeks</b> <br class=br>Every 4 weeks: 71.2%<br class=br>Every 2 weeks: 79.7%<br class=br>P: 10.4%<br class=br>A 40 mg every 2 weeks: 54.4%</td></tr><tr><a name=d32882e1495 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1497 class=n-a></a><b>Apremilast</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1502 class=n-a></a>Phosphodiesterase-4 inhibitor </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1505 class=n-a></a>PALACE 3<sup><a href="#ref-72">72</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1511 class=n-a></a>20 mg twice daily<br class=br>30 mg twice daily<br class=br>VS<br class=br>P </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1520 class=n-a></a>505</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1524 class=n-a></a> <b>Female (%)</b> <br class=br>20 mg: 53<br class=br>30 mg: 53<br class=br>P: 54<br class=br> <br class=br> <b>Mean age</b> <br class=br>20 mg: 49.5<br class=br>30 mg: 49.9<br class=br>P: 49.5<br class=br> <br class=br> <b>Mean duration PsA (years)</b> <br class=br>20 mg twice daily: 7.7<br class=br>30 mg twice daily: 7.5<br class=br>P: 6.8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1564 class=n-a></a> <b>Week 16</b> <br class=br>20 mg twice daily: 28%<br class=br>30 mg twice daily: 42%<br class=br>P: 18%<br class=br> <br class=br> <b>Week 52</b> <br class=br>20 mg twice daily: 56%<br class=br>30 mg twice daily: 63%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1588 class=n-a></a><b>Week 16</b><br class=br>20 mg twice daily: 20%<br class=br>30 mg twice daily: 21%<br class=br>P: 8%<br class=br> <br class=br> <b>Week 52</b> <br class=br>20 mg twice daily: 29%<br class=br>30 mg twice daily: 39%</td></tr><tr><a name=d32882e1611 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1613 class=n-a></a><b>Abatacept</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1617 class=n-a></a>CTLA4Ig inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1620 class=n-a></a>ASTRAEA trial<sup><a href="#ref-73">73</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1626 class=n-a></a>ABA SC 125 mg /week<br class=br>VS<br class=br>P</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1633 class=n-a></a>424<br class=br> <br class=br>60% prior TNFi</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1641 class=n-a></a> <b>Mean age</b> <br class=br>ABA: 51<br class=br>P: 49.8<br class=br> <br class=br> <b>Female (%)</b> <br class=br>ABA: 56.8<br class=br>P: 53.1<br class=br> <br class=br> <b>Mean duration PsA (years)</b> <br class=br>ABA: 8.3<br class=br>P: 8.8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1675 class=n-a></a> <b>24 weeks</b> <br class=br>ABA: 39.4%<br class=br>P: 22.3%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1685 class=n-a></a> <b>24 weeks</b> <br class=br>ABA: 16.4%<br class=br>P: 10.1%</td></tr><tr><a name=d32882e1697 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1699 class=n-a></a><b>Tofacitinib</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1703 class=n-a></a>Inhibitor JAK3-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1706 class=n-a></a>OPAL BROADEN<sup><a href="#ref-74">74</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1712 class=n-a></a>Tofacitinib at a 5 mg dose by mouth twice daily<br class=br> <br class=br>Tofacitinib<br class=br>10 mg dose by mouth twice daily<br class=br> <br class=br>A at a 40 mg dose SC once every 2 weeks<br class=br> <br class=br>P with a blinded switch to<br class=br>5 mg tofacitinib dose at 3 months or P with a blinded switch to the 10 mg<br class=br>tofacitinib dose at 3 months </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1734 class=n-a></a>394</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1738 class=n-a></a> <b>Mean age</b> <br class=br>5 mg: 49.4<br class=br>10 mg: 46.9<br class=br>P: 47.7<br class=br>A: 47.4<br class=br> <br class=br> <b>Female (%)</b> <br class=br>5 mg: 53<br class=br>10 mg: 60<br class=br>P: 53<br class=br>A: 47<br class=br> <br class=br> <b>Mean duration PsA (years)</b> <br class=br>5 mg: 7.3<br class=br>10 mg: 5.4<br class=br>P: 6.4<br class=br>A: 5.3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1785 class=n-a></a> <b>12 weeks</b> <br class=br>5 mg: 50%<br class=br>10 mg: 61%<br class=br>P: 33%<br class=br>A: 52%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1799 class=n-a></a> <b>12 weeks</b> <br class=br>5 mg: 43%<br class=br>10 mg: 44%<br class=br>P: 15%<br class=br>A: 39%</td></tr><tr><a name=d32882e1814 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1816 class=n-a></a><b>Adalimumab</b></td><td colspan=1 rowspan=1><a name=d32882e1820 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1822 class=n-a></a>GENOVESE 2007<sup><a href="#ref-85">85</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1828 class=n-a></a>A 40 mg EOW<br class=br>VS<br class=br>P<br class=br> <br class=br>Followed by open label study: A 40 mg EOW</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1839 class=n-a></a>100</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1843 class=n-a></a> <b>Mean age</b> <br class=br>A: 50.a<br class=br>P: 47.7<br class=br> <br class=br> <b>Male (%)</b> <br class=br>A: 57<br class=br>P: 51<br class=br> <br class=br> <b>Mean duration PsA (years)</b> <br class=br>A: 7.5<br class=br>P: 7.2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1877 class=n-a></a> <b>Week 12</b> <br class=br>A: 39%<br class=br>P: 16%</td><td colspan=1 rowspan=1><a name=d32882e1887 class=n-a></a></td></tr><tr><a name=d32882e1890 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1892 class=n-a></a> <b>Etanercept</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1897 class=n-a></a>Fusion protein. Extracellular binding portion of TNF receptor (p75) dimerized on human IgG1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1900 class=n-a></a>Mease 2000<sup><a href="#ref-86">86</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1906 class=n-a></a>E 25 mg SC twice week<br class=br>VS<br class=br>P</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1913 class=n-a></a>60</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1917 class=n-a></a> <b>Mean age</b><br class=br>E: 46<br class=br>P: 43.5<br class=br> <br class=br> <b>Male (%)</b> <br class=br>E: 53<br class=br>P: 60<br class=br> <br class=br> <b>Mean duration PsA (years)</b> <br class=br>E: 9.0<br class=br>P: 9.5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1950 class=n-a></a> <b>12 weeks</b> <br class=br>E: 73%<br class=br>P: 13%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1960 class=n-a></a> <b>12 weeks</b> <br class=br>E: 26%<br class=br>P: 0%</td></tr><tr><a name=d32882e1971 class=n-a></a><td colspan=1 rowspan=1><a name=d32882e1973 class=n-a></a></td><td colspan=1 rowspan=1><a name=d32882e1975 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1977 class=n-a></a>Mease 2004<sup><a href="#ref-87">87</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1983 class=n-a></a>E 25 mg SC twice weekly × 24 weeks<br class=br>VS<br class=br>P</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1990 class=n-a></a>205</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e1994 class=n-a></a> <b>Mean age</b> <br class=br>E: 47.8<br class=br>P: 47.3<br class=br> <br class=br> <b>Male (%)</b> <br class=br>E: 57<br class=br>P: 45<br class=br> <br class=br> <b>Mean duration</b> <b>PsA (years)</b> <br class=br>E: 9.0<br class=br>P: 9.2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2031 class=n-a></a>E: 59%<br class=br>P: 15%<br class=br>Sustained at 24 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2038 class=n-a></a>E: 23%<br class=br>P: 3%</td></tr><tr><a name=d32882e2044 class=n-a></a><td colspan=1 rowspan=1><a name=d32882e2046 class=n-a></a></td><td colspan=1 rowspan=1><a name=d32882e2048 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2050 class=n-a></a>Extension study<br class=br>48 weeks<sup><a href="#ref-88">88</a></sup></td><td colspan=1 rowspan=1><a name=d32882e2058 class=n-a></a></td><td colspan=1 rowspan=1><a name=d32882e2060 class=n-a></a></td><td colspan=1 rowspan=1><a name=d32882e2063 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2065 class=n-a></a>E: 64%<br class=br>P: 50%</td><td colspan=1 rowspan=1><a name=d32882e2070 class=n-a></a></td></tr><tr><a name=d32882e2073 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2075 class=n-a></a> <b>Infliximab</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2081 class=n-a></a>Mouse-human chimeric anti TNF monoclonal Ab.<br class=br>Binds soluble and membrane-bound TNFα</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2086 class=n-a></a>IMPACT<sup><a href="#ref-89">89</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2092 class=n-a></a>I 5 mg/kg IV at weeks 0, 2, 6, and 14<br class=br>VS<br class=br>P</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2099 class=n-a></a>104</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2103 class=n-a></a> <b>Mean age</b> <br class=br>I: 45.7<br class=br>P: 45.2<br class=br> <br class=br> <b>Male (%)</b> <br class=br>I: 58<br class=br>P: 58<br class=br> <br class=br> <b>Mean duration PsA</b> (<b>years)</b> <br class=br>I: 16.9<br class=br>P: 19.4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2140 class=n-a></a> <b>Week 16</b> <br class=br>I: 67,3%<br class=br>P: 11.5 %</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2150 class=n-a></a> <b>Week 16</b> <br class=br>I: 68%<br class=br>P: 0%</td></tr><tr><a name=d32882e2162 class=n-a></a><td colspan=1 rowspan=1><a name=d32882e2164 class=n-a></a></td><td colspan=1 rowspan=1><a name=d32882e2166 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2168 class=n-a></a>IMPACT 2<sup><a href="#ref-56">56</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2174 class=n-a></a>I IV 5 mg/kg at weeks 0, 2, 6, 14, and 22<br class=br>VS<br class=br>P</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2181 class=n-a></a>200</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2185 class=n-a></a> <b>Mean age</b> <br class=br>I: 47.1<br class=br>P: 46.5<br class=br> <br class=br> <b>Male (%)</b> <br class=br>I: 71<br class=br>P: 51<br class=br> <br class=br> <b>Mean duration PsA (years)</b> <br class=br>I: 8.4<br class=br>P: 7.5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2219 class=n-a></a> <b>Week 12</b> <br class=br>I: 58%<br class=br>P: 11%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2229 class=n-a></a>I: 64%<br class=br>P: 2%</td></tr><tr><a name=d32882e2235 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2237 class=n-a></a><b>Golimumab</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2241 class=n-a></a>Human monoclonal Ab.<br class=br>Binds soluble and membrane-bound TNFα</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2246 class=n-a></a>GO-REVEAL<sup><a href="#ref-90">90</a>,</sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2253 class=n-a></a>50 mg or 100 mg SC<br class=br> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2258 class=n-a></a>405</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2262 class=n-a></a> <b>Mean age</b> <br class=br>50 mg: 45.7<br class=br>100 mg: 48.2<br class=br>P: 47.0<br class=br> <br class=br> <b>Male (%)</b> <br class=br>50 mg: 89<br class=br>100 mg: 86<br class=br>P: 69<br class=br> <b>Mean duration PsA (years)</b> <br class=br>50 mg: 7.2<br class=br>100 mg: 7.7<br class=br>P: 7.6 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2300 class=n-a></a> <b>Week 14</b> <br class=br>50 mg: 51%<br class=br>100 mg: 45%<br class=br>P: 9%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2312 class=n-a></a> <b>Week 14</b> <br class=br>50 mg: 40%<br class=br>100 mg: 58%<br class=br>P: 2.5%</td></tr><tr><a name=d32882e2325 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2327 class=n-a></a><b>Ustekinumab</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2331 class=n-a></a>Human mAb IgG1.<br class=br>Binds to p40 of IL-12 and IL-23</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2336 class=n-a></a>PSUMMIT 1<sup><a href="#ref-91">91</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2342 class=n-a></a>Previous inadequate response to MTX<br class=br>45 mg<br class=br>90 mg<br class=br>P<br class=br>Week 0, 4, and every 12 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2353 class=n-a></a>615</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2357 class=n-a></a> <b>Mean age</b> <br class=br>45 mg: 48<br class=br>90 mg: 47<br class=br>P: 48<br class=br> <br class=br> <b>Male (%)</b> <br class=br>45 mg: 51.7<br class=br>90 mg: 56.9<br class=br>P: 52.4<br class=br> <br class=br> <b>Mean duration PsA (years)</b> <br class=br>45 mg: 3.4<br class=br>90 mg: 4.9<br class=br>P: 3.6</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2397 class=n-a></a> <b>Week 24</b> <br class=br>45 mg: 42.2%<br class=br>90 mg: 49.5%<br class=br>P: 22.8%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2409 class=n-a></a> <b>Week 24</b> <br class=br>45 mg: 57.2%<br class=br>90 mg: 62.4%<br class=br>P: 11%</td></tr><tr><a name=d32882e2422 class=n-a></a><td colspan=1 rowspan=1><a name=d32882e2424 class=n-a></a></td><td colspan=1 rowspan=1><a name=d32882e2426 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2428 class=n-a></a>PSUMMIT 2<sup><a href="#ref-92">92</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2434 class=n-a></a>45 mg<br class=br>90 mg<br class=br>P<br class=br>Week 0, 4, and every 12 weeks<br class=br>VS<br class=br>P with cross over to UST 45 mg at week 24, 28, and 40 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2447 class=n-a></a>312</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2451 class=n-a></a> <b>Female (%)</b> <br class=br>45 mg: 53.4<br class=br>90 mg: 53.3<br class=br>P: 51<br class=br> <br class=br> <b>Mean age</b> <br class=br>45 mg: 49<br class=br>90 mg: 48<br class=br>P: 48<br class=br> <br class=br> <b>Mean duration PsA (years)</b> <br class=br>45 mg: 5.3<br class=br>90 mg: 4.5<br class=br>P: 5.5 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2491 class=n-a></a>45 mg: 43.7%<br class=br>90 mg: 43.8%<br class=br>P: 20.2%<br class=br> <br class=br> <b>Anti-TNF exposure</b> <br class=br>45 mg: 36.7%<br class=br>90 mg: 34.5%<br class=br>P: 14.5%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2512 class=n-a></a>45 mg: 51.3%<br class=br>90 mg: 55.6%<br class=br>P: 5%<br class=br> <br class=br> <b>Anti-TNF exposure</b> <br class=br>45 mg: 45.5 %<br class=br>90 mg: 48.8%<br class=br>P: 2.0%</td></tr><tr><a name=d32882e2534 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2536 class=n-a></a>Apremilast</td><td colspan=1 rowspan=1><a name=d32882e2539 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2541 class=n-a></a>PALACE 4<sup><a href="#ref-93">93</a></sup><br class=br> <br class=br>DMARD-naive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2551 class=n-a></a>20 mg/twice daily<br class=br>30 mg/twice daily<br class=br>VS<br class=br>P<br class=br>At week 16 or 24, P patients were rerandomized to apremilast</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2562 class=n-a></a>527</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2566 class=n-a></a> <b>Mean age</b> <br class=br>20 mg: 49.2<br class=br>30 mg: 48.4<br class=br>P: 50.5<br class=br> <br class=br> <b>Female (%)</b> <br class=br>20 mg: 54.3<br class=br>30 mg: 54.5<br class=br>P: 48.9<br class=br> <br class=br> <b>Mean duration PsA (years)</b> <br class=br>20 mg: 15.3<br class=br>30 mg: 15.4<br class=br>P: 16.8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2606 class=n-a></a> <b>Week 16</b> <br class=br>20 mg: 28%<br class=br>30 mg: 30.7%<br class=br>P: 15.9<b>%</b> <br class=br> <br class=br> <b>Week 52</b> <br class=br>20 mg: 53.4%<br class=br>30 mg: 58.7%<br class=br> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2635 class=n-a></a> <b>Week 16</b> <br class=br>20 mg: 17.3%<br class=br>30 mg: 25.7%<br class=br>P: 10.8%<br class=br> <br class=br> <b>Week 52</b> <br class=br>20 mg: 41%<br class=br>30 mg: 31.9%</td></tr><tr><a name=d32882e2660 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2662 class=n-a></a><b>Secukinumab</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2667 class=n-a></a>IL-17 inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2670 class=n-a></a>FUTURE 2 - <sup><a href="#ref-94">94</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2676 class=n-a></a>Sec SC<br class=br>300 mg<br class=br>150 mg<br class=br>75 mg<br class=br>VS<br class=br>P<br class=br>Week 1, 2, 34, and every 4 weeks after</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2692 class=n-a></a>397</td><td colspan=1 rowspan=1><a name=d32882e2696 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2698 class=n-a></a>Sec75: 50.3%<br class=br>Sec150: 64.4%<br class=br>Sec300: 69.4%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2705 class=n-a></a>Sec75: 58.4%<br class=br>Sec150: 73.3%<br class=br>Sec300: 79.5%</td></tr><tr><a name=d32882e2714 class=n-a></a><td colspan=1 rowspan=1><a name=d32882e2716 class=n-a></a></td><td colspan=1 rowspan=1><a name=d32882e2718 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2720 class=n-a></a>FUTURE 5<sup><a href="#ref-65">65</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2726 class=n-a></a>Sec 300 mg<br class=br>or 150 mg with loading dose, 150 mg without<br class=br>loading dose, or P. All groups received Sec or<br class=br>P at baseline, weeks 1, 2, and 3 and then every<br class=br>4 weeks from week 4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2737 class=n-a></a>996</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2741 class=n-a></a> <b>Mean age</b> <br class=br>300 mg + loading dose: 48.9<br class=br>150 mg + loading dose: 48.4<br class=br>150 mg: 48.8<br class=br>P: 49<br class=br> <br class=br> <b>Female (%)</b> <br class=br>300 mg + loading dose: 51.4<br class=br>150 mg + loading dose: 49.5<br class=br>150 mg: 4.5.9<br class=br>P: 51.5<br class=br> <br class=br> <b>Mean duration PsA (years)</b> <br class=br>300 mg + loading dose: 48.9<br class=br>150 mg + loading dose: 48.4<br class=br>150 mg: 48.8<br class=br>P: 49</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2788 class=n-a></a> <b>Week 16</b> <br class=br>300 mg with loading dose: 62.6%<br class=br> 150 mg with loading dose: 55.5%<br class=br> 150 mg without loading dose: 59.5%<br class=br> P: 27.4%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d32882e2802 class=n-a></a> <b>Week 16</b> <br class=br>300 mg + loading dose: 70%<br class=br>150 mg + loading dose: 60<br class=br>150 mg: 58.1<br class=br>P: 12.3</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d32882e2821 class=n-a></a><p id=FN1> ABA, Abatacept; A, adalimumab; E, etanercept; EOW, every other week; I, infliximab; IV, intravenous; mAb, monoclonal antibody; mg, milligrams; P, placebo; PsA, psoriatic arthritis; SC, subcutaneous; Sec, secukinumab; TNFi, tumour necrosis factor inhibitor; VS, versus</p></div></div></div></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d32882e2833 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d33498>References</h2><div class="section ref-list"><a name=d32882e2833 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d32882e2840 class=n-a></a>Zlatkovic-Svenda M, Kerimovic-Morina D, Stojanovic RM: Psoriatic arthritis classification criteria: Moll and Wright, ESSG and CASPAR -- a comparative study. <i>Acta Reumatol Port.</i> 2013; <b>38</b>(3): 172–8. <a target=xrefwindow id=d32882e2848 href="http://www.ncbi.nlm.nih.gov/pubmed/24149013">PubMed Abstract </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d32882e2857 class=n-a></a>Kurd SK, Gelfand JM: The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. <i>J Am Acad Dermatol.</i> 2009; <b>60</b>(2): 218–24. <a target=xrefwindow id=d32882e2865 href="http://www.ncbi.nlm.nih.gov/pubmed/19022533">PubMed Abstract </a> | <a target=xrefwindow id=d32882e2868 href="https://doi.org/10.1016/j.jaad.2008.09.022">Publisher Full Text </a> | <a target=xrefwindow id=d32882e2871 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4762027">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d32882e2880 class=n-a></a>Alinaghi F, Calov M, Kristensen LE, <i> et al.</i>: Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. <i>J Am Acad Dermatol.</i> 2019; <b>80</b>(1): 251–265.e19. <a target=xrefwindow id=d32882e2891 href="http://www.ncbi.nlm.nih.gov/pubmed/29928910">PubMed Abstract </a> | <a target=xrefwindow id=d32882e2894 href="https://doi.org/10.1016/j.jaad.2018.06.027">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d32882e2903 class=n-a></a>Eder L, Haddad A, Rosen CF, <i> et al.</i>: The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. <i>Arthritis Rheumatol.</i> 2016; <b>68</b>(4): 915–23. <a target=xrefwindow id=d32882e2914 href="http://www.ncbi.nlm.nih.gov/pubmed/26555117">PubMed Abstract </a> | <a target=xrefwindow id=d32882e2917 href="https://doi.org/10.1002/art.39494">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d32882e2926 class=n-a></a>Husni E, Michael M: Oxford textbook of Psoriatic arthritis: Epidemiology of PsA. Oxford university. 2018. <a target=xrefwindow id=d32882e2928 href="https://global.oup.com/academic/product/oxford-textbook-of-psoriatic-arthritis-9780198737582?cc=in&amp;lang=en&amp;">Reference Source</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d32882e2938 class=n-a></a>Sukhov A, Adamopoulos IE, Maverakis E: Interactions of the Immune System with Skin and Bone Tissue in Psoriatic Arthritis: A Comprehensive Review. <i>Clin Rev Allergy Immunol.</i> 2016; <b>51</b>(1): 87–99. <a target=xrefwindow id=d32882e2946 href="http://www.ncbi.nlm.nih.gov/pubmed/26780035">PubMed Abstract </a> | <a target=xrefwindow id=d32882e2949 href="https://doi.org/10.1007/s12016-016-8529-8">Publisher Full Text </a> | <a target=xrefwindow id=d32882e2952 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6080719">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d32882e2961 class=n-a></a>Raychaudhuri SK, Maverakis E, Raychaudhuri SP: Diagnosis and classification of psoriasis. <i>Autoimmun Rev.</i> 2014; <b>13</b>(4–5): 490–5. <a target=xrefwindow id=d32882e2969 href="https://doi.org/10.1016/j.autrev.2014.01.008">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d32882e2978 class=n-a></a>Taylor W, Gladman D, Helliwell P, <i> et al.</i>: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. <i>Arthritis Rheum.</i> 2006; <b>54</b>(8): 2665–73. <a target=xrefwindow id=d32882e2989 href="http://www.ncbi.nlm.nih.gov/pubmed/16871531 ">PubMed Abstract </a> | <a target=xrefwindow id=d32882e2992 href="https://doi.org/10.1002/art.21972">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d32882e3001 class=n-a></a>Tillett W, Jadon D, Shaddick G, <i> et al.</i>: Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. <i>Ann Rheum Dis.</i> 2013; <b>72</b>(8): 1358–61. <a target=xrefwindow id=d32882e3012 href="http://www.ncbi.nlm.nih.gov/pubmed/23291384 ">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3015 href="https://doi.org/10.1136/annrheumdis-2012-202608">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718276755"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3024 class=n-a></a>Haroon M, Gallagher P, FitzGerald O: Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. <i>Ann Rheum Dis.</i> 2015; <b>74</b>(6): 1045–50. <a target=xrefwindow id=d32882e3032 href="http://www.ncbi.nlm.nih.gov/pubmed/24525911">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3035 href="https://doi.org/10.1136/annrheumdis-2013-204858">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718276755">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733116124"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3048 class=n-a></a>Kaine J, Song X, Kim G, <i> et al.</i>: Higher Incidence Rates of Comorbidities in Patients with Psoriatic Arthritis Compared with the General Population Using U.S. Administrative Claims Data. <i>J Manag Care Spec Pharm.</i> 2019; <b>25</b>(1): 122–32. <a target=xrefwindow id=d32882e3059 href="http://www.ncbi.nlm.nih.gov/pubmed/29694270">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3062 href="https://doi.org/10.18553/jmcp.2018.17421">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733116124">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d32882e3076 class=n-a></a>Reich K, Krüger K, Mössner R, <i> et al.</i>: Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. <i>Br J Dermatol.</i> 2009; <b>160</b>(5): 1040–7. <a target=xrefwindow id=d32882e3087 href="http://www.ncbi.nlm.nih.gov/pubmed/19210498">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3090 href="https://doi.org/10.1111/j.1365-2133.2008.09023.x">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1158171"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3099 class=n-a></a>Wilson FC, Icen M, Crowson CS, <i> et al.</i>: Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study. <i>Arthritis Rheum.</i> 2009; <b>61</b>(2): 233–9. <a target=xrefwindow id=d32882e3110 href="http://www.ncbi.nlm.nih.gov/pubmed/19177544">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3113 href="https://doi.org/10.1002/art.24172">Publisher Full Text </a> | <a target=xrefwindow id=d32882e3117 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3061343">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1158171">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d32882e3130 class=n-a></a>Gladman DD, Anhorn KA, Schachter RK, <i> et al.</i>: HLA antigens in psoriatic arthritis. <i>J Rheumatol.</i> 1986; <b>13</b>(3): 586–92. <a target=xrefwindow id=d32882e3141 href="http://www.ncbi.nlm.nih.gov/pubmed/3735281">PubMed Abstract </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d32882e3150 class=n-a></a>Haroon M, Kirby B, FitzGerald O: High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. <i>Ann Rheum Dis.</i> 2013; <b>72</b>(5): 736–40. <a target=xrefwindow id=d32882e3158 href="http://www.ncbi.nlm.nih.gov/pubmed/22730367">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3161 href="https://doi.org/10.1136/annrheumdis-2012-201706">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d32882e3170 class=n-a></a>Chandran V, Schentag CT, Gladman DD: Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. <i>Arthritis Rheum.</i> 2007; <b>57</b>(8): 1560–3. <a target=xrefwindow id=d32882e3178 href="http://www.ncbi.nlm.nih.gov/pubmed/18050230">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3181 href="https://doi.org/10.1002/art.23104">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d32882e3190 class=n-a></a>Chandran V, Schentag CT, Gladman DD: Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. <i>J Rheumatol.</i> 2008; <b>35</b>(10): 2069–70; author reply 2070. <a target=xrefwindow id=d32882e3198 href="http://www.ncbi.nlm.nih.gov/pubmed/18843760">PubMed Abstract </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d32882e3208 class=n-a></a>Coates LC, Aslam T, Al Balushi F, <i> et al.</i>: Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). <i>Br J Dermatol.</i> 2013; <b>168</b>(4): 802–7. <a target=xrefwindow id=d32882e3219 href="http://www.ncbi.nlm.nih.gov/pubmed/23311587">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3222 href="https://doi.org/10.1111/bjd.12190">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734324690"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3231 class=n-a></a>Iragorri N, Hazlewood G, Manns B, <i> et al.</i>: Psoriatic arthritis screening: a systematic review and meta-analysis. <i>Rheumatology (Oxford).</i> 2019; <b>58</b>(4): 692–707. <a target=xrefwindow id=d32882e3242 href="http://www.ncbi.nlm.nih.gov/pubmed/30380111">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3245 href="https://doi.org/10.1093/rheumatology/key314">Publisher Full Text </a> | <a target=xrefwindow id=d32882e3249 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6434376">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734324690">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d32882e3262 class=n-a></a>Tom BD, Chandran V, Farewell VT, <i> et al.</i>: Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2). <i>J Rheumatol.</i> 2015; <b>42</b>(5): 841–6. <a target=xrefwindow id=d32882e3273 href="http://www.ncbi.nlm.nih.gov/pubmed/25834198">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3276 href="https://doi.org/10.3899/jrheum.140857">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d32882e3285 class=n-a></a>Tinazzi I, Adami S, Zanolin EM, <i> et al.</i>: The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. <i>Rheumatology (Oxford).</i> 2012; <b>51</b>(11): 2058–63. <a target=xrefwindow id=d32882e3296 href="http://www.ncbi.nlm.nih.gov/pubmed/22879464">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3299 href="https://doi.org/10.1093/rheumatology/kes187">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736575181"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3308 class=n-a></a>Burlando M, Cozzani E, Schiavetti I, <i> et al.</i>: The STRIPP questionnaire (Screening Tool for Rheumatologic Investigation in Psoriatic Patients) as a new tool for the diagnosis of early psoriatic arthritis. <i>G Ital Dermatol Venereol.</i> 2017. <a target=xrefwindow id=d32882e3316 href="http://www.ncbi.nlm.nih.gov/pubmed/29192470">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3319 href="https://doi.org/10.23736/S0392-0488.17.05745-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736575181">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732126185"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3332 class=n-a></a>Salaffi F, Di Carlo M, Luchetti MM, <i> et al.</i>: A validation study of the Simple Psoriatic Arthritis Screening (SiPAS) questionnaire to screen psoriasis patients for psoriatic arthritis. <i>Clin Exp Rheumatol.</i> 2018; <b>36</b>(1): 127–35. <a target=xrefwindow id=d32882e3343 href="http://www.ncbi.nlm.nih.gov/pubmed/29148421">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732126185">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1101065"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3357 class=n-a></a>Gisondi P, Tinazzi I, El-Dalati G, <i> et al.</i>: Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. <i>Ann Rheum Dis.</i> 2008; <b>67</b>(1): 26–30. <a target=xrefwindow id=d32882e3368 href="http://www.ncbi.nlm.nih.gov/pubmed/17720726">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3371 href="https://doi.org/10.1136/ard.2007.075101">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1101065">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734241790"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3384 class=n-a></a>Tom S, Zhong Y, Cook R, <i> et al.</i>: Development of a Preliminary Ultrasonographic Enthesitis Score in Psoriatic Arthritis - GRAPPA Ultrasound Working Group. <i>J Rheumatol.</i> 2019; <b>46</b>(4): 384–90. <a target=xrefwindow id=d32882e3395 href="http://www.ncbi.nlm.nih.gov/pubmed/30323008">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3398 href="https://doi.org/10.3899/jrheum.171465">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734241790">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d32882e3411 class=n-a></a>Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. <i>Clin Pharmacol Ther.</i> 2001; <b>69</b>(3): 89–95. <a target=xrefwindow id=d32882e3419 href="http://www.ncbi.nlm.nih.gov/pubmed/11240971">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3422 href="https://doi.org/10.1067/mcp.2001.113989">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d32882e3431 class=n-a></a>Okada Y, Han B, Tsoi LC, <i> et al.</i>: Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes. <i>Am J Hum Genet.</i> 2014; <b>95</b>(2): 162–72. <a target=xrefwindow id=d32882e3442 href="http://www.ncbi.nlm.nih.gov/pubmed/25087609 ">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3445 href="https://doi.org/10.1016/j.ajhg.2014.07.002">Publisher Full Text </a> | <a target=xrefwindow id=d32882e3449 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4129407">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d32882e3458 class=n-a></a>Eder L, Chandran V, Pellet F, <i> et al.</i>: Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. <i>Ann Rheum Dis.</i> 2012; <b>71</b>(1): 50–5. <a target=xrefwindow id=d32882e3469 href="http://www.ncbi.nlm.nih.gov/pubmed/21900282">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3472 href="https://doi.org/10.1136/ard.2011.155044">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13370005"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3481 class=n-a></a>Winchester R, Minevich G, Steshenko V, <i> et al.</i>: HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. <i>Arthritis Rheum.</i> 2012; <b>64</b>(4): 1134–44. <a target=xrefwindow id=d32882e3492 href="http://www.ncbi.nlm.nih.gov/pubmed/22006066">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3495 href="https://doi.org/10.1002/art.33415">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13370005">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d32882e3509 class=n-a></a>Haroon M, Winchester R, Giles JT, <i> et al.</i>: Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. <i>Ann Rheum Dis.</i> 2015; <b>75</b>(1): 155–62. <a target=xrefwindow id=d32882e3520 href="http://www.ncbi.nlm.nih.gov/pubmed/25261574">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3523 href="https://doi.org/10.1136/annrheumdis-2014-205461">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d32882e3532 class=n-a></a>Stuart PE, Nair RP, Tsoi LC, <i> et al.</i>: Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. <i>Am J Hum Genet.</i> 2015; <b>97</b>(6): 816–36. <a target=xrefwindow id=d32882e3543 href="http://www.ncbi.nlm.nih.gov/pubmed/26626624">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3546 href="https://doi.org/10.1016/j.ajhg.2015.10.019">Publisher Full Text </a> | <a target=xrefwindow id=d32882e3550 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4678416">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d32882e3559 class=n-a></a>Pollock RA, Abji F, Liang K, <i> et al.</i>: Gene Expression Differences between Psoriasis Patients with and without Inflammatory Arthritis. <i>J Invest Dermatol.</i> 2015; <b>135</b>(2): 620–3. <a target=xrefwindow id=d32882e3570 href="http://www.ncbi.nlm.nih.gov/pubmed/25243786">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3573 href="https://doi.org/10.1038/jid.2014.414">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d32882e3582 class=n-a></a>Chandran V, Cook RJ, Edwin J, <i> et al.</i>: Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. <i>Rheumatology (Oxford).</i> 2010; <b>49</b>(7): 1399–405. <a target=xrefwindow id=d32882e3593 href="http://www.ncbi.nlm.nih.gov/pubmed/20421218">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3596 href="https://doi.org/10.1093/rheumatology/keq105">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d32882e3605 class=n-a></a>Abji F, Pollock RA, Liang K, <i> et al.</i>: Brief Report: CXCL10 Is a Possible Biomarker for the Development of Psoriatic Arthritis Among Patients With Psoriasis. <i>Arthritis Rheumatol.</i> 2016; <b>68</b>(12): 2911–6. <a target=xrefwindow id=d32882e3616 href="http://www.ncbi.nlm.nih.gov/pubmed/27389865">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3619 href="https://doi.org/10.1002/art.39800">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d32882e3628 class=n-a></a>Muntyanu A, Abji F, Liang K, <i> et al.</i>: Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis. <i>Arthritis Res Ther.</i> 2016; <b>18</b>(1): 296. <a target=xrefwindow id=d32882e3639 href="http://www.ncbi.nlm.nih.gov/pubmed/27964744">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3642 href="https://doi.org/10.1186/s13075-016-1196-6">Publisher Full Text </a> | <a target=xrefwindow id=d32882e3646 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5154157">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d32882e3656 class=n-a></a>Ritchlin CT, Haas-Smith SA, Li P, <i> et al.</i>: Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. <i>J Clin Invest..</i> 2003; <b>111</b>(6): 821–31. <a target=xrefwindow id=d32882e3667 href="http://www.ncbi.nlm.nih.gov/pubmed/12639988">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3670 href="https://doi.org/10.1172/JCI16069">Publisher Full Text </a> | <a target=xrefwindow id=d32882e3674 href="http://www.ncbi.nlm.nih.gov/pmc/articles/153764">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2630958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3683 class=n-a></a>Chiu YG, Shao T, Feng C, <i> et al.</i>: CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. <i>Arthritis Res Ther.</i> 2010; <b>12</b>(1): R14. <a target=xrefwindow id=d32882e3694 href="http://www.ncbi.nlm.nih.gov/pubmed/20102624">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3697 href="https://doi.org/10.1186/ar2915">Publisher Full Text </a> | <a target=xrefwindow id=d32882e3701 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2875642">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2630958">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d32882e3714 class=n-a></a>Vasey FB, Deitz C, Fenske NA, <i> et al.</i>: Possible involvement of group A streptococci in the pathogenesis of psoriatic arthritis. <i>J Rheumatol.</i> 1982; <b>9</b>(5): 719–22. <a target=xrefwindow id=d32882e3725 href="http://www.ncbi.nlm.nih.gov/pubmed/6757423">PubMed Abstract </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1090833"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3734 class=n-a></a>Pattison E, Harrison BJ, Griffiths CE, <i> et al.</i>: Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. <i>Ann Rheum Dis.</i> 2007; <b>67</b>(5): 672–6. <a target=xrefwindow id=d32882e3745 href="http://www.ncbi.nlm.nih.gov/pubmed/17823200">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3748 href="https://doi.org/10.1136/ard.2007.073932">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1090833">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d32882e3761 class=n-a></a>Eder L, Law T, Chandran V, <i> et al.</i>: Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. <i>Arthritis Care Res (Hoboken).</i> 2011; <b>63</b>(8): 1091–7. <a target=xrefwindow id=d32882e3772 href="http://www.ncbi.nlm.nih.gov/pubmed/21560259 ">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3775 href="https://doi.org/10.1002/acr.20496">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726701780"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3784 class=n-a></a>Love TJ, Zhu Y, Zhang Y, <i> et al.</i>: Obesity and the risk of psoriatic arthritis: a population-based study. <i>Ann Rheum Dis.</i> 2012; <b>71</b>(8): 1273–7. <a target=xrefwindow id=d32882e3795 href="http://www.ncbi.nlm.nih.gov/pubmed/22586165">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3798 href="https://doi.org/10.1136/annrheumdis-2012-201299">Publisher Full Text </a> | <a target=xrefwindow id=d32882e3802 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3645859">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726701780">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d32882e3816 class=n-a></a>Simon D, Faustini F, Kleyer A, <i> et al.</i>: Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. <i>Ann Rheum Dis.</i> 2016; <b>75</b>(4): 660–6. <a target=xrefwindow id=d32882e3827 href="http://www.ncbi.nlm.nih.gov/pubmed/25653201">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3830 href="https://doi.org/10.1136/annrheumdis-2014-206347">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d32882e3839 class=n-a></a>Ritchlin CT, Colbert RA, Gladman DD: Psoriatic Arthritis. <i>N Engl J Med.</i> 2017; <b>376</b>(10): 957–70. <a target=xrefwindow id=d32882e3847 href="http://www.ncbi.nlm.nih.gov/pubmed/28273019">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3850 href="https://doi.org/10.1056/NEJMra1505557">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d32882e3859 class=n-a></a>FitzGerald O, Haroon M, Giles JT, <i> et al.</i>: Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. <i>Arthritis Res Ther.</i> 2015; <b>17</b>: 115. <a target=xrefwindow id=d32882e3870 href="http://www.ncbi.nlm.nih.gov/pubmed/25948071">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3873 href="https://doi.org/10.1186/s13075-015-0640-3">Publisher Full Text </a> | <a target=xrefwindow id=d32882e3877 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4422545">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d32882e3886 class=n-a></a>Nelson GW, Martin MP, Gladman D, <i> et al.</i>: Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. <i>J Immunol.</i> 2004; <b>173</b>(7): 4273–6. <a target=xrefwindow id=d32882e3897 href="http://www.ncbi.nlm.nih.gov/pubmed/15383555">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3900 href="https://doi.org/10.4049/jimmunol.173.7.4273">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d32882e3909 class=n-a></a>Chandran V, Bull SB, Pellett FJ, <i> et al.</i>: Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. <i>Rheumatology (Oxford).</i> 2014; <b>53</b>(2): 233–9. <a target=xrefwindow id=d32882e3920 href="http://www.ncbi.nlm.nih.gov/pubmed/24185760">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3923 href="https://doi.org/10.1093/rheumatology/ket296">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d32882e3932 class=n-a></a>Ray-Jones H, Eyre S, Barton A, <i> et al.</i>: One SNP at a Time: Moving beyond GWAS in Psoriasis. <i>J Invest Dermatol.</i> 2016; <b>136</b>(3): 567–73. <a target=xrefwindow id=d32882e3943 href="http://www.ncbi.nlm.nih.gov/pubmed/26811024">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3946 href="https://doi.org/10.1016/j.jid.2015.11.025">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725340801"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3956 class=n-a></a>Bowes J, Budu-Aggrey A, Huffmeier U, <i> et al.</i>: Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nat Commun.</i> 2015; <b>6</b>: 6046. <a target=xrefwindow id=d32882e3967 href="http://www.ncbi.nlm.nih.gov/pubmed/25651891">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3970 href="https://doi.org/10.1038/ncomms7046">Publisher Full Text </a> | <a target=xrefwindow id=d32882e3974 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4327416">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725340801">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718289870"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e3987 class=n-a></a>de Vlam K, Gottlieb AB, Mease PJ: Current concepts in psoriatic arthritis: Pathogenesis and management. <i>Acta Derm Venereol.</i> 2014; <b>94</b>(6): 627–34. <a target=xrefwindow id=d32882e3995 href="http://www.ncbi.nlm.nih.gov/pubmed/24573106">PubMed Abstract </a> | <a target=xrefwindow id=d32882e3998 href="https://doi.org/10.2340/00015555-1833">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718289870">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d32882e4011 class=n-a></a>Leijten EFA, van Kempen TS, Boes M, <i> et al.</i>: Brief Report: Enrichment of Activated Group 3 Innate Lymphoid Cells in Psoriatic Arthritis Synovial Fluid. <i>Arthritis Rheumatol.</i> 2015; <b>67</b>(10): 2673–8. <a target=xrefwindow id=d32882e4022 href="http://www.ncbi.nlm.nih.gov/pubmed/26137857">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4025 href="https://doi.org/10.1002/art.39261">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d32882e4034 class=n-a></a>Lowes MA, Suárez-Fariñas M, Krueger JG: Immunology of psoriasis. <i>Annu Rev Immunol.</i> 2014; <b>32</b>: 227–55. <a target=xrefwindow id=d32882e4042 href="http://www.ncbi.nlm.nih.gov/pubmed/24655295">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4045 href="https://doi.org/10.1146/annurev-immunol-032713-120225">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4048 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4229247">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d32882e4057 class=n-a></a>Coates LC, Kavanaugh A, Mease PJ, <i> et al.</i>: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis Rheumatol.</i> 2016; <b>68</b>(5): 1060–71. <a target=xrefwindow id=d32882e4068 href="http://www.ncbi.nlm.nih.gov/pubmed/26749174">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4071 href="https://doi.org/10.1002/art.39573">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d32882e4080 class=n-a></a>Soriano ER, McHugh NJ: Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. <i>J Rheumatol.</i> 2006; <b>33</b>(7): 1422–30. <a target=xrefwindow id=d32882e4088 href="http://www.ncbi.nlm.nih.gov/pubmed/16724372">PubMed Abstract </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d32882e4098 class=n-a></a>Mease P: Management of psoriatic arthritis: The therapeutic interface between rheumatology and dermatology. <i>Curr Rheumatol Rep.</i> 2006; <b>8</b>(5): 348–54. <a target=xrefwindow id=d32882e4106 href="http://www.ncbi.nlm.nih.gov/pubmed/16973108">PubMed Abstract </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726159431"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e4115 class=n-a></a>Elyoussfi S, Thomas BJ, Ciurtin C: Tailored treatment options for patients with psoriatic arthritis and psoriasis: Review of established and new biologic and small molecule therapies. <i>Rheumatol Int.</i> 2016; <b>36</b>(5): 603–12. <a target=xrefwindow id=d32882e4123 href="http://www.ncbi.nlm.nih.gov/pubmed/26892034">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4126 href="https://doi.org/10.1007/s00296-016-3436-0">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4129 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4839046">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726159431">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d32882e4142 class=n-a></a>Antoni C, Krueger GG, de Vlam K, <i> et al.</i>: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. <i>Ann Rheum Dis.</i> 2005; <b>64</b>(8): 1150–7. <a target=xrefwindow id=d32882e4153 href="http://www.ncbi.nlm.nih.gov/pubmed/15677701">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4156 href="https://doi.org/10.1136/ard.2004.032268">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4160 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1755609">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d32882e4169 class=n-a></a>Kavanaugh A, McInnes I, Mease P, <i> et al.</i>: Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. <i>Arthritis Rheum.</i> 2009; <b>60</b>(4): 976–86. <a target=xrefwindow id=d32882e4180 href="http://www.ncbi.nlm.nih.gov/pubmed/19333944">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4183 href="https://doi.org/10.1002/art.24403">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728639701"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e4192 class=n-a></a>Kavanaugh A, Husni ME, Harrison DD, <i> et al.</i>: Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study. <i>Arthritis Rheumatol.</i> 2017; <b>69</b>(11): 2151–61. <a target=xrefwindow id=d32882e4203 href="http://www.ncbi.nlm.nih.gov/pubmed/28805045">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4206 href="https://doi.org/10.1002/art.40226">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4210 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5765449">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728639701">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718074595"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e4223 class=n-a></a>Mease PJ, Fleischmann R, Deodhar AA, <i> et al.</i>: Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). <i>Ann Rheum Dis.</i> 2013; <b>73</b>(1): 48–55. <a target=xrefwindow id=d32882e4234 href="http://www.ncbi.nlm.nih.gov/pubmed/23942868">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4237 href="https://doi.org/10.1136/annrheumdis-2013-203696">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4241 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3888622">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718074595">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d32882e4255 class=n-a></a>Mease PJ, Gladman DD, Ritchlin CT, <i> et al.</i>: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. <i>Arthritis Rheum.</i> 2005; <b>52</b>(10): 3279–89. <a target=xrefwindow id=d32882e4266 href="http://www.ncbi.nlm.nih.gov/pubmed/16200601">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4269 href="https://doi.org/10.1002/art.21306">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d32882e4278 class=n-a></a>Dougados M, Combe B, Braun J, <i> et al.</i>: A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. <i>Ann Rheum Dis.</i> 2010; <b>69</b>(8): 1430–5. <a target=xrefwindow id=d32882e4289 href="http://www.ncbi.nlm.nih.gov/pubmed/20511606">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4292 href="https://doi.org/10.1136/ard.2009.121533">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2111958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e4301 class=n-a></a>Sterry W, Ortonne JP, Kirkham B, <i> et al.</i>: Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. <i>BMJ.</i> 2010; <b>340</b>: c147. <a target=xrefwindow id=d32882e4312 href="http://www.ncbi.nlm.nih.gov/pubmed/20124563">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4315 href="https://doi.org/10.1136/bmj.c147">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2111958">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d32882e4328 class=n-a></a>Mease PJ, McInnes IB, Kirkham B, <i> et al.</i>: Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. <i>N Engl J Med.</i> 2015; <b>373</b>(14): 1329–39. <a target=xrefwindow id=d32882e4339 href="http://www.ncbi.nlm.nih.gov/pubmed/26422723">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4342 href="https://doi.org/10.1056/NEJMoa1412679">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725609985"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e4351 class=n-a></a>McInnes IB, Mease PJ, Kirkham B, <i> et al.</i>: Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet.</i> 2015; <b>386</b>(9999): 1137–46. <a target=xrefwindow id=d32882e4362 href="http://www.ncbi.nlm.nih.gov/pubmed/26135703">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4365 href="https://doi.org/10.1016/S0140-6736(15)61134-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725609985">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d32882e4378 class=n-a></a>Mease P, van der Heijde D, Landewé R, <i> et al.</i>: Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(6): 890–7. <a target=xrefwindow id=d32882e4389 href="http://www.ncbi.nlm.nih.gov/pubmed/29550766">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4392 href="https://doi.org/10.1136/annrheumdis-2017-212687">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4396 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5965348">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d32882e4406 class=n-a></a>Mease PJ, van der Heijde D, Ritchlin CT, <i> et al.</i>: Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. <i>Ann Rheum Dis.</i> 2017; <b>76</b>(1): 79–87. <a target=xrefwindow id=d32882e4417 href="http://www.ncbi.nlm.nih.gov/pubmed/27553214">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4420 href="https://doi.org/10.1136/annrheumdis-2016-209709">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4424 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5264219">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d32882e4433 class=n-a></a>Gladman DD, Orbai AM, Klitz U, <i> et al.</i>: Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. <i>Arthritis Res Ther.</i> 2019; <b>21</b>(1): 38. <a target=xrefwindow id=d32882e4444 href="http://www.ncbi.nlm.nih.gov/pubmed/30696483">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4447 href="https://doi.org/10.1186/s13075-019-1831-0">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4451 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6350390">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d32882e4460 class=n-a></a>Nash P, Kirkham B, Okada M, <i> et al.</i>: Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet.</i> 2017; <b>389</b>(10086): 2317–27. <a target=xrefwindow id=d32882e4471 href="http://www.ncbi.nlm.nih.gov/pubmed/28551073">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4474 href="https://doi.org/10.1016/S0140-6736(17)31429-0">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718283036"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e4483 class=n-a></a>Kavanaugh A, Ritchlin C, Rahman P, <i> et al.</i>: Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. <i>Ann Rheum Dis.</i> 2014; <b>73</b>(6): 1000–6. <a target=xrefwindow id=d32882e4494 href="http://www.ncbi.nlm.nih.gov/pubmed/24553909">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4497 href="https://doi.org/10.1136/annrheumdis-2013-204741">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4501 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4033146">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718283036">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718325084"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e4514 class=n-a></a>Kavanaugh A, Mease PJ, Gomez-Reino JJ, <i> et al.</i>: Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. <i>Ann Rheum Dis.</i> 2014; <b>73</b>(6): 1020–6. <a target=xrefwindow id=d32882e4525 href="http://www.ncbi.nlm.nih.gov/pubmed/24595547">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4528 href="https://doi.org/10.1136/annrheumdis-2013-205056">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4532 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4033106">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718325084">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d32882e4545 class=n-a></a>Cutolo M, Myerson GE, Fleischmann RM, <i> et al.</i>: A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. <i>J Rheumatol.</i> 2016; <b>43</b>(9): 1724–34. <a target=xrefwindow id=d32882e4556 href="http://www.ncbi.nlm.nih.gov/pubmed/27422893">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4559 href="https://doi.org/10.3899/jrheum.151376">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d32882e4569 class=n-a></a>Edwards CJ, Blanco FJ, Crowley J, <i> et al.</i>: Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). <i>Ann Rheum Dis.</i> 2016; <b>75</b>(6): 1065–73. <a target=xrefwindow id=d32882e4580 href="http://www.ncbi.nlm.nih.gov/pubmed/26792812">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4583 href="https://doi.org/10.1136/annrheumdis-2015-207963">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4587 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4893110">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d32882e4596 class=n-a></a>Mease PJ, Gottlieb AB, van der Heijde D, <i> et al.</i>: Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. <i>Ann Rheum Dis.</i> 2017; <b>76</b>(9): 1550–8. <a target=xrefwindow id=d32882e4607 href="http://www.ncbi.nlm.nih.gov/pubmed/28473423">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4610 href="https://doi.org/10.1136/annrheumdis-2016-210724">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4614 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5561378">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d32882e4623 class=n-a></a>Mease P, Hall A, FitzGerald O, <i> et al.</i>: Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. <i>New Engl J Med.</i> 2017; <b>377</b>(16): 1537–1550. <a target=xrefwindow id=d32882e4634 href="http://www.ncbi.nlm.nih.gov/pubmed/29045212">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4637 href="https://doi.org/10.1056/NEJMoa1615975">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d32882e4646 class=n-a></a>Gladman D, Rigby W, Azevedo VF, <i> et al.</i>: Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. <i>N Engl J Med.</i> 2017; <b>377</b>(16): 1525–36. <a target=xrefwindow id=d32882e4657 href="http://www.ncbi.nlm.nih.gov/pubmed/29045207">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4660 href="https://doi.org/10.1056/NEJMoa1615977">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d32882e4669 class=n-a></a>Mease PJ, Gladman DD, Collier DH, <i> et al.</i>: Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. <i>Arthritis Rheumatol.</i> 2019; <b>71</b>(7): 1112–1124. <a target=xrefwindow id=d32882e4680 href="http://www.ncbi.nlm.nih.gov/pubmed/30747501">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4683 href="https://doi.org/10.1002/art.40851">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4687 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6618246">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d32882e4696 class=n-a></a>The Janssen Pharmaceutical Companies of Johnson &amp; Johnson. 2019. <a target=xrefwindow id=d32882e4698 href="https://www.janssen.com/">Reference Source</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d32882e4708 class=n-a></a>Papp KA, Blauvelt A, Bukhalo M, <i> et al.</i>: Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis <i>N Engl J Med.</i> 2017; <b>376</b>(16): 1551–60. <a target=xrefwindow id=d32882e4719 href="http://www.ncbi.nlm.nih.gov/pubmed/28423301">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4722 href="https://doi.org/10.1056/NEJMoa1607017">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d32882e4731 class=n-a></a>Mease PJ, Kellner H, Morita A, <i> et al.</i>: Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(Suppl): A200.</span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d32882e4749 class=n-a></a>Mease P, Coates LC, Helliwell PS, <i> et al.</i>: Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet.</i> 2018; <b>392</b>(10162): 2367–77. <a target=xrefwindow id=d32882e4760 href="http://www.ncbi.nlm.nih.gov/pubmed/30360969">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4763 href="https://doi.org/10.1016/S0140-6736(18)32483-8">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d32882e4772 class=n-a></a>Kimball AB, Gladman D, Gelfand JM, <i> et al.</i>: National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. <i>J Am Acad Dermatol.</i> 2008; <b>58</b>(6): 1031–42. <a target=xrefwindow id=d32882e4783 href="http://www.ncbi.nlm.nih.gov/pubmed/18313171">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4786 href="https://doi.org/10.1016/j.jaad.2008.01.006">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4790 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3716382">Free Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d32882e4799 class=n-a></a>Mishra S, Kancharla H, Dogra S, <i> et al.</i>: Comparison of four validated psoriatic arthritis screening tools in diagnosing psoriatic arthritis in patients with psoriasis (COMPAQ Study). <i>Br J Dermatol.</i> 2017; <b>176</b>(3): 765–70. <a target=xrefwindow id=d32882e4810 href="http://www.ncbi.nlm.nih.gov/pubmed/27500901">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4813 href="https://doi.org/10.1111/bjd.14929">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d32882e4822 class=n-a></a>Ibrahim GH, Buch MH, Lawson C, <i> et al.</i>: Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: The Psoriasis Epidemiology Screening Tool (PEST) questionnaire. <i>Clin Exp Rheumatol.</i> 2009; <b>27</b>(3): 469–74. <a target=xrefwindow id=d32882e4833 href="http://www.ncbi.nlm.nih.gov/pubmed/19604440">PubMed Abstract </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d32882e4843 class=n-a></a>Machado PM, Raychaudhuri SP: Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. <i>Best Pract Res Clin Rheumatol.</i> 2014; <b>28</b>(5): 711–28. <a target=xrefwindow id=d32882e4851 href="http://www.ncbi.nlm.nih.gov/pubmed/25488780">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4854 href="https://doi.org/10.1016/j.berh.2014.10.004">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d32882e4863 class=n-a></a>Genovese MC, Mease PJ, Thomson GT, <i> et al.</i>: Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. <i>J Rheumatol.</i> 2007; <b>34</b>(5): 1040–50. <a target=xrefwindow id=d32882e4874 href="http://www.ncbi.nlm.nih.gov/pubmed/17444593">PubMed Abstract </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718205969"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e4883 class=n-a></a>Mease PJ, Goffe BS, Metz J, <i> et al.</i>: Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. <i>Lancet.</i> 2000; <b>356</b>(9227): 385–90. <a target=xrefwindow id=d32882e4894 href="http://www.ncbi.nlm.nih.gov/pubmed/10972371">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4897 href="https://doi.org/10.1016/S0140-6736(00)02530-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718205969">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d32882e4910 class=n-a></a>Mease PJ, Kivitz AJ, Burch FX, <i> et al.</i>: Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. <i>Arthritis Rheum.</i> 2004; <b>50</b>(7): 2264–72. <a target=xrefwindow id=d32882e4921 href="http://www.ncbi.nlm.nih.gov/pubmed/15248226">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4924 href="https://doi.org/10.1002/art.20335">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d32882e4933 class=n-a></a>Mease PJ, Kivitz AJ, Burch FX, <i> et al.</i>: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. <i>J Rheumatol.</i> 2006; <b>33</b>(4): 712–21. <a target=xrefwindow id=d32882e4944 href="http://www.ncbi.nlm.nih.gov/pubmed/16463435">PubMed Abstract </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d32882e4953 class=n-a></a>Antoni CE, Kavanaugh A, Kirkham B, <i> et al.</i>: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). <i>Arthritis Rheum.</i> 2005; <b>52</b>(4): 1227–36. <a target=xrefwindow id=d32882e4964 href="http://www.ncbi.nlm.nih.gov/pubmed/15818699">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4967 href="https://doi.org/10.1002/art.20967">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d32882e4977 class=n-a></a>Kavanaugh A, McInnes IB, Mease PJ, <i> et al.</i>: Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. <i>Ann Rheum Dis.</i> 2013; <b>72</b>(11): 1777–85. <a target=xrefwindow id=d32882e4988 href="http://www.ncbi.nlm.nih.gov/pubmed/23161902">PubMed Abstract </a> | <a target=xrefwindow id=d32882e4991 href="https://doi.org/10.1136/annrheumdis-2012-202035">Publisher Full Text </a> | <a target=xrefwindow id=d32882e4995 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3812864">Free Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718020573"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e5004 class=n-a></a>McInnes IB, Kavanaugh A, Gottlieb AB, <i> et al.</i>: Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. <i>Lancet.</i> 2013; <b>382</b>(9894): 780–9. <a target=xrefwindow id=d32882e5015 href="http://www.ncbi.nlm.nih.gov/pubmed/23769296">PubMed Abstract </a> | <a target=xrefwindow id=d32882e5018 href="https://doi.org/10.1016/S0140-6736(13)60594-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718020573">F1000 Recommendation</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d32882e5031 class=n-a></a>Ritchlin C, Rahman P, Kavanaugh A, <i> et al.</i>: Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. <i>Ann Rheum Dis.</i> 2014; <b>73</b>(6): 990–9. <a target=xrefwindow id=d32882e5042 href="http://www.ncbi.nlm.nih.gov/pubmed/24482301">PubMed Abstract </a> | <a target=xrefwindow id=d32882e5045 href="https://doi.org/10.1136/annrheumdis-2013-204655">Publisher Full Text </a> | <a target=xrefwindow id=d32882e5049 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4033144">Free Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733027840"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e5058 class=n-a></a>Wells AF, Edwards CJ, Kivitz AJ, <i> et al.</i>: Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: Results of the randomized, placebo-controlled PALACE 4 trial. <i>Rheumatology (Oxford).</i> 2018; <b>57</b>: 1253–63. <a target=xrefwindow id=d32882e5069 href="http://www.ncbi.nlm.nih.gov/pubmed/29635379">PubMed Abstract </a> | <a target=xrefwindow id=d32882e5072 href="https://doi.org/10.1093/rheumatology/key032">Publisher Full Text </a> | <a target=xrefwindow id=d32882e5076 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6014136">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733027840">F1000 Recommendation</a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731686267"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d32882e5089 class=n-a></a>McInnes IB, Mease PJ, Ritchlin CT, <i> et al.</i>: Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. <i>Rheumatology (Oxford).</i> 2017; <b>56</b>(11): 1993–2003. <a target=xrefwindow id=d32882e5100 href="http://www.ncbi.nlm.nih.gov/pubmed/28968735">PubMed Abstract </a> | <a target=xrefwindow id=d32882e5103 href="https://doi.org/10.1093/rheumatology/kex301">Publisher Full Text </a> | <a target=xrefwindow id=d32882e5107 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5850284">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731686267">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 20 Sep 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1665&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1665&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada<br/> <sup>2</sup> Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada<br/> <p> <div class=margin-bottom> Vanessa Ocampo D <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Dafna Gladman <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1665/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 20 Sep 2019, 8:1665 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.19144.1">https://doi.org/10.12688/f1000research.19144.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Ocampo D V and Gladman D. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=20979 data-id=19144 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19144.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1665/v1/pdf?article_uuid=15c91bca-429c-461e-8661-7646383e3cc6" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.19144.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Ocampo D V and Gladman D. Psoriatic arthritis [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1665 (<a href="https://doi.org/10.12688/f1000research.19144.1" target=_blank>https://doi.org/10.12688/f1000research.19144.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=19144 id=mobile-track-article-signin-19144 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19144?target=/articles/8-1665"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20979 /> <input name=articleId type=hidden value=19144 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Giampiero Girolomon</strong>, Department of Medicine, Section of Dermatology and Venereology, University of Verona, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Luis R Espinoza</strong>, Section of Rheumatology, LSU Health Sciences Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 20 Sep 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1665&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1665&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=56925-53737></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=56926-53738></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1665/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>20 Sep 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Giampiero Girolomon</strong>, Department of Medicine, Section of Dermatology and Venereology, University of Verona, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Luis R Espinoza</strong>, Section of Rheumatology, LSU Health Sciences Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1665&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1665/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Psoriatic arthritis".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1665/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1665/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1665/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Ocampo D V and Gladman D');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1665/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1665",
            templates : {
                twitter : "Psoriatic arthritis. Ocampo D V and Gladman D, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1665/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Psoriatic arthritis", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Psoriatic arthritis", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/19144/20979")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "20979");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "53737": 0,
                           "53738": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "56c50ea8-294c-4a8f-9d8e-aacad448bdb7";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1665.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1665.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1665.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1665.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1665.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>